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Abstract
EFFECTS OF CANNABINOID RECEPTOR INTERACTING PROTEIN (CRIP1a) ON
CANNABINOID (CB1) RECEPTOR FUNCTION.
By Tricia Hardt Smith, B.S., M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2009.
Major Director: Dana E. Selley, Ph.D., Department of Pharmacology and Toxicology
This dissertation examines modulation of cannabinoid CB1 receptor function by
Cannabinoid Receptor Interacting Protein (CRIP1a), a novel protein that binds the Cterminus of CB1 receptors. In Human embryonic kidney cells expressing human CB1
receptors (hCB1-HEK) and hCB1-HEK cells stably co-expressing CRIP1a (hCB1-HEKCRIP1a), quantitative immunoblotting revealed a CRIP1a/CB1 molar ratio of 5.4 and 0.37,
respectively, with no difference in CB1 receptor expression. To test the hypothesis that
CRIP1a modulates CB1 receptor signaling, G-protein and effector activity were examined
with and without full, partial and inverse agonists. [35S]GTPS binding, which measures
G-protein-coupled receptor (GPCR)-mediated G-protein activation, showed that CRIP1a
inhibited constitutive CB1 receptor activity, as indicated by the decreased effect of the
inverse agonist SR141716A. CRIP1a also decreased CB1 receptor-mediated G-protein
activation by high efficacy agonists, whereas moderate and low efficacy agonists were
unaffected. In experiments varying Na+ concentration, CRIP1a decreased spontaneous Gprotein activation at low Na+ concentrations, where spontaneous GPCR activity is
highest. This effect was eliminated by pertussis toxin pre-treatment, indicating that
CRIP1a only inhibits GPCR-mediated activity. To determine whether CRIP1a modulates

xv
receptor adaptation, hCB1-HEK (±CRIP1a) cells were pretreated with WIN or THC. Both
ligands desensitized CB1 receptor-mediated G-protein activation, but desensitization was
unaffected by CRIP1a. In contrast, CRIP1a attenuated downregulation of CB1 receptor
binding sites by WIN, but not THC. Downstream, CRIP1a attenuated constitutive CB1
receptor-mediated inhibition of cAMP, as indicated by elimination of SR141716Astimulated cAMP, without affecting agonist-induced cAMP inhibition. Constitutive
inhibition was not due to endocannabinoids because LC-ESI-MS-MS did not detect
endocannabinoids in hCB1-HEK (±CRIP1a) cells. To determine whether effects of
CRIP1a were conserved among cell types, Chinese Hamster Ovary cells expressing CB1
receptors were stably co-transfected with CRIP1a, and had a CRIP1a/CB1 receptor molar
ratio of 15 and 1900 with and without CRIP1a over-expression, respectively. In this
model, CRIP1a inhibited constitutive CB1 receptor-mediated G-protein activity, but
activation by agonists was enhanced, suggesting CRIP1a effects were dependent on
stoichiometry of CRIP1a/CB1 receptor or cell type. Overall, these results indicate that
CRIP1a decreases constitutive CB1 receptor activity, modulates agonist efficacy, and
inhibits CB1 receptor downregulation, in a ligand- and cellular environment-dependent
manner.
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Chapter 1. Introduction

1.1 Introduction to Cannabinoids and the Cannabinoid Receptors
Cannabis, or marijuana, use has been documented in human history as early as
2600 B.C. when in ancient Chinese texts, such as the Nei Ching, its use was
recommended in cramping, pain, and to stop hemorrhage during childbirth. Cannabis
was also used in ancient Egypt for a variety of medical reasons, including childbirth,
enemas, eye medications and ointments in bandages. Ancient Indian texts, as early as
1200 B.C., describe cannabis as a sacred grass, from which bhang, the drink prepared
from cannabis, is used for its anxiolytic properties, „antiphlegmatic‟ properties and in
religious rites. In the 19th century its use spread to Europe and the Americas as a
psychoactive substance. The medical utilization of cannabis also flourished during these
times, until cannabis was banned in 1937 due to concerns over its abuse potential
(Mechoulam 1986). Recently, an 11 g sample of ancient cannabis was found in a 2700year-old tomb excavated in China. High performance liquid chromatography confirmed
the presence of psychoactive constituents, verifying cannabis use for medicinal or
divinatory purposes early in human history (Russo et al. 2008).
In 1988, the main psychoactive component of marijuana, 9-tetrahydrocannabinol
(THC) was found to exert its affects by binding to cannabinoid (CB) receptors in the
brain (Devane et al. 1988). Currently, the potential medical benefits of cannabinoids and
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the endocannabinoid system are on the forefront of drug discovery (Mackie 2006).
Dronabinol, a synthetic form of THC, has been proven affective in cancer patients for
chemotherapy-induced nausea and vomiting. Dronabinol is also used to treat AIDSrelated anorexia. Other therapeutic effects of the drug include analgesia, antitumor
effects, mood elevation, muscle relaxation, and relief of insomnia (Walsh et al. 2003).
Human placebo-controlled trials of the drug Sativex, a buccal spray containing THC and
another cannabinoid cannabidiol, have proven effective for the spasticity and neuropathic
pain associated with multiple sclerosis (Barnes 2006). The upregulation of the
endocannabinoid pathway in response to neuronal injury has sparked interest in the use of
cannabinoids in neurodegenerative disorders (Bahr et al. 2006). CB1 receptor antagonists
have shown promising results in anti-obesity studies (Palamara et al. 2006). Overall, the
CB1 receptor is an important therapeutic target that warrants further study.
Understanding how the CB1 receptor is regulated may allow the selective targeting of
beneficial effects while decreasing unwanted side effects, such as anxiety, short-term
memory impairment and decreased motor coordination.
Cannabinoid receptors are of particular importance in the arena of drug abuse.
Cannabis is the most commonly used illicit drug in the United States, with more than
40% of Americans age 12 and older having tried cannabis at least once (Administration
2003). In addition to mediating the effects of THC, cannabinoid receptors are also
involved in mediating the rewarding properties of other drugs. The cannabinoid and
opioid system modulate each other‟s ability to activate dopamine (DA) release in the
ascending mesocorticolimbic projections of the ventral tegmental area (VTA), which is
activated by most drugs of abuse (Maldonado and Rodriguez de Fonseca 2002;
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Maldonado et al. 2006). In mice with a genetic knockout of CB1, the major cannabinoid
receptor in the CNS, the reinforcing effects of morphine were reduced in intravenous
self-administration tests (Ledent et al. 1999). The CB1 receptor is also of importance in
nicotine addiction, as CB1 knockout in mice blocked the rewarding properties of nicotine
in conditioned place preference studies (Castane et al. 2002). In addition, cannabinoid
agonists stimulate voluntary alcohol consumption in alcohol-preferring Sardinian and
Wistar rats (Gallate et al. 1999; Colombo et al. 2002). Although CB1 knockout mice did
not exhibit decreased self-administration of cocaine and amphetamine acutely (Cossu et
al. 2001), they did show evidence of lower cocaine reinforcing efficacy on a progressive
ratio schedule of self-administration (Soria et al. 2005). This type of schedule evaluates
the reinforcing strength of a drug, and lower break points indicate a decreased motivation
for maintaining cocaine-seeking behavior.
Rimonabant, a CB1 antagonist also known as SR141716A, has shown
considerable promise as a drug addiction treatment. Rimonabant decreased opioid selfadministration (Navarro et al. 2001) and conditioned place preference in rodents (De
Vries et al. 2003). In human studies, rimonabant was significantly effective in tobacco
cessation studies in North America [Studies with Rimonabant and Tobacco use in North
America (STRATUS-North America)] and Europe (Fernandez and Allison 2004).
Rimonabant reduced conditioned reinstatement of ethanol-seeking behavior in rats
(Cippitelli et al. 2005), and decreased cocaine relapse after cocaine re-exposure (De Vries
and Schoffelmeer 2005).
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1.2 Cannabinoid Receptor Location, Function and Ligands
Two cannabinoid receptors have been cloned to date; CB1 (Matsuda et al. 1990)
and CB2 (Munro et al. 1993). CB1 is one of the most abundant receptors in the brain
(Ester Fride 2003), and it is also found in the periphery (Devane et al. 1988). CB2 is
found mainly within the immune system (Munro et al. 1993) and has limited expression
in the central nervous system (CNS) (Van Sickle et al. 2005).
CB1 receptors are found throughout the central nervous system, with particularly
high expression densities in the hippocampus, cortex, caudate-putamen, globus pallidus,
substantia nigra and cerebellum, and with moderate expression in periaquidctal grey,
spinal cord and hypothalamus (Herkenham et al. 1991; Sim et al. 1996; Tsou et al. 1998).
The immediate effects of marijuana intoxication reflect the functions of these brain
regions, including impairment of short term memory, emotional disruption, hypomotility,
reward, catalepsy, decreased motor coordination, antinociception and hypothermia
(Dewey 1986; Hollister 1986).
The various cannabinoid ligands show a strong correlation between their affinity
for CB1 receptor binding and their potency for in vivo effects (Compton et al. 1993). CB1
receptors have also been linked to a myriad of processes including brain development
(Rueda et al. 2002), short-term synaptic plasticity (depolarized-induced suppression of
inhibition (DSI) (Wilson and Nicoll 2001) and depolarized-induced suppression of
excitation (DSE) (Kreitzer and Regehr 2001), and facilitation of long term potentiation
(Carlson et al. 2002).
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Figure 1. The chemical structures of cannabinoid ligands. Phytocannabinoids include
9-tetrahydrocannabinol (THC), cannabidiol (CBD), and 9-tetrahydrocannabivarin
(THCV). Classic synthetic cannabinoids include HU210 and nabilone. A non-classical
synthetic cannabinoid is CP 55,940. An aminoalkykindol is WIN 55,212-2. A nantradol
is levonantradol. Endogenous cannabinoids (eicosanoids) include anandamide (AEA)
and 2-arachidonoyl glycerol (2-AG). The diarylpyrazoles, which are inverse agonists,
include SR141716A (SR1) and SR144528 (SR2).
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The first ligands discovered for the CB1 receptor were isolated from the Cannabis
plant, and are termed phytocannabinoids; the main psychoactive component isolated from
Cannabis being 9-tetrahydrocannabinol (THC) (Gaoni and Mechoulam 1971) (Figure 1).
The discovery that the l-stereoisomer of THC, and not the d-stereoisomer, was
responsible for the biological activity of THC suggested the involvement of a receptor, as
drug-receptor interactions are stereoselective (Hollister 1974). The involvement of a
receptor was later confirmed by saturable, high affinity, stereospecific binding sites for
the cannabinoid radioligand [3H]CP 55,940 in mouse brain membranes (Devane et al.
1988). Cannabidiol (CBD), a phytocannabinoid found in high abundance in Cannabis,
has a very low affinity for cannabinoid receptors but does act as an antagonist of
cannabinoid receptor agonists (Thomas et al. 2007). Therapeutically, cannabidiol is not
psychoactive, but is effective in the treatment of convulsions, inflammation, nausea and
anxiety (Mechoulam et al. 2007). 9-Tetrahydrocannabivarin (THCV), also highly
abundant in Cannabis, is a behaviorally active phytocannabinoid that acts as an weak
partial agonist at CB1 receptors, and is able to antagonize the effects of THC (Pertwee et
al. 2007).
A myriad of synthetic cannabinoids have been synthesized (Figure 1), including
synthetic classical cannabinoids that are structurally similar to THC, including HU210,
which is greater than 100 times more potent than THC and has a longer duration of action
(Felder et al. 1995). Another synthetic cannabinoid similar to THC, nabilone, marketed
as Cesmet, is approved for use nausea and vomiting associated with cancer chemotherapy
(Slatkin 2007). Non-classical synthetic cannabinoids that are somewhat structurally
dissimilar to classical cannabinoids have also been synthesized, including the bicyclic CP
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55,940 (CP) which is greater than 100 times more potent than THC in behavioral tests
(Wiley et al. 1995) and CB1 receptor binding (Gatley et al. 1997). Another non-classical,
synthetic class of cannabinoids is the aminoalkylindoles, such as WIN 55,212,2 (WIN),
which are structurally dissimilar to classical or bicyclic cannabinoids, yet bind potently to
CB receptors and elicit strong behavioral effects (Kuster et al. 1993; Pacher et al. 2006).
In the 1980s, Pfizer Pharmaceuticals introduced another structural class somewhat similar
to the THC class termed the nantradols, which includes levonantradol and
dextronantradol. Levonantradol (Levo) is equipotent to 30 times more potent than THC
in behavioral tests, while dextronantradol is weak to inactive (Little et al. 1988).
In 1992, the first endogenous ligand for the CB1 receptor was discovered, Narachidonoyl ethanolamine. This compound was also named anandamide, after the
Sanskrit word ananda, meaning “bliss, delight”. (Devane et al. 1992). Three years later
another endogenous cannabinoid, 2-arachidonoylglycerol (2-AG) was independently codiscovered (Mechoulam et al. 1995; Sugiura et al. 1995). Anandamide is modestly
selective for the CB1 receptor. Anandamide may be partially synthesized in vivo via Nacyl phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) in response to
elevations of intracellular Ca+2. However, NAPE-PLD knock-out mice were still able to
produce reduced levels of N-acyl ethanolamines, suggesting that alternative pathways for
the synthesis of anandamide exist (Leung et al. 2006). Anandamide is broken down by
fatty acid amide hyrdrolase (Cravatt et al. 2001). 2-AG binds to CB1 and CB2 with
similar affinities, and is synthesized from diacylglycerol by diacyglycerol lipase (DAGL)
(Bisogno et al. 2003), and is broken down primarily by monoacylcyclyceride lipase
(MGL) (Dinh et al. 2002). Many other endogenous lipids with endocannabinoid activity
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have also been reported (Bisogno et al. 2005; Pacher et al. 2006). One example is 2arachidonyl glyceryl ether, commonly known as noladin ether (Nol Eth), which was
isolated from porcine brain in 2001. It is psychoactive and binds strongly to the CB1
receptor and weakly to the CB2 receptor (Hanus et al. 2001).
The first CB1 receptor antagonist, discovered by Sanofi Aventis, was the
diarylpyrazole SR141716A (SR1) (Rinaldi-Carmona et al. 1994). This development was
followed by the discovery of another diarylpyrazole selective for the CB2 receptor,
SR144528 (SR2) (Rinaldi-Carmona et al. 1998). Both antagonists were later shown to
have inverse agonist properties, meaning that they inhibit the basal, agonist independent
activity of the receptor to which they bind (Bouaboula et al. 1997; Bouaboula et al.
1999).
1.3 Cannabinoid Receptor Signaling
Cannabinoid receptors are members of the G-protein coupled receptor (GPCR)
superfamily, which are proteins with seven transmembrane alpha-helical domains, as well
as an extracellular N terminus and an intracellular C-terminus (Matsuda et al. 1990).
These membrane bound receptors are activated by extracellular ligands, transducing the
signal to the cell interior by activation of heterotrimeric guanine nucleotide bindin Gproteins (G-proteins) (Gilman 1987). The cannabinoid receptors specifically activate the
pertussis (PTX) toxin sensitive Gi/Go subfamily of proteins, (Howlett et al. 1986), of
which there are four types: Gi1, Gi2, Gi3, and Go (Albert and Robillard 2002).
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Figure 2. G-protein coupled receptor signaling. Prior to ligand binding, the receptor is
inactive and G-proteins exist in the form of an  heterotrimer. The inactive G
subunit is bound to GDP. Upon ligand activation, the receptor changes to an active
conformation (green), thereby activating G-proteins. GDP is exchanged for GTP and the
G and G dissociate from one another and the receptor and are free to activate
downstream signaling events. The cycle concludes when the GTPase activity of the G
subunit dephosphorylates GTP to GDP, allowing the G subunit to return to its resting
confirmation and reassociate with G.
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A basic introduction to GPCR signaling is as follows (Figure 2). Prior to
activation, G-proteins exist in the form of an  heterotrimer, and are associated with
the membrane via post-translational lipid moieties (Chen and Manning 2001). The G
subunit is bound to GDP. Upon ligand binding, the receptor changes conformation, and
becomes activated, thereby activating the G-protein. GDP is exchanged for GTP, and the
G and the G subunits dissociate from one another and the receptor and are free to
activate downstream signaling events. The G and G remain bound to each other as a
dimer. The cycle concludes when the GTPase activity of the G subunit
dephosphorylates GTP to GDP, allowing the G subunit to return to its resting
conformation. G and G reassociate, returning the G-protein to its original inactivated
state (Rockhold 2002). GPCRs act catalytically; each GPCR can activate multiple Gproteins over time. For instance the catalytic amplification factor of the cannabinoid CB1
receptor has been calculated as 3 in striatum, as determined by comparing the Bmax value
of agonist binding to the Bmax value of agonist-simulated [35S]GTPS binding. It is
important to note that although this calculated amplification factor might not be true
under all conditions, it is useful to compare among different receptors in the same tissue
when assayed under identical conditions. For example, cannabinoid receptors exhibited
low catalytic amplification factors compared to the µ-opioid and -opioid receptors in the
striatum, which exhibited an amplification factor of 17 and 22, respectively (Sim et al.
1996). Moreover, the amplification factor of CB1 receptors, calculated by this same
approach, varied among different brain regions (Breivogel et al. 1997).
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Figure 3. Equilibrium ternary complex model of ligand-receptor-G-protein interaction.
GPCRs exist in equilibrium between an inactive (R) and active (R*) state. The
isomerization from R to R* enables GPCRs to dissociate from GDP from G-proteins (G),
which is the rate limiting step in GPCR signaling. The conversion from R to R* may
happen in the presence of an agonist (A) or spontaneously, in the case of constitutively
active receptors. After GDP dissociation, GTP binds to the G subunit of the G-protein
heterotrimer, causing its dissociation into the active components of GGTP, G, and its
dissociation from the receptor.
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Despite the seeming simplicity of the G-protein activation cycle, the nuances
generated by the multitude of binding equilibria for all the possible protein-protein and
ligand-protein interactions are more accurately represented in the equilibrium ternary
complex model of ligand-receptor-G-protein interaction (Figure 3) (Leff 1995; Leff et al.
1997; Howlett 2004; Mukhopadhyay and Howlett 2005). GPCRs exist in equilibrium
between an inactivate (R) and active state (R*) (Leff 1995). The isomerization from R to
R* enables GPCRs to promote GDP dissociation from G-proteins, which is the ratelimiting step in GPCR signaling (Gilman 1987). Agonist (A) binds to the receptor, also
an equilibrium event, which may or may not be precoupled to the G-protein heterotrimer
bound to GDP (GGDP). Agonist bound receptor enters into equilibrium with the “ternary
complex”, which is agonist bound to receptor coupled with a GDP-bound G-protein
heterotrimer. This ternary complex stabilizes the receptor in its active conformation (R*)
that promotes the dissociation of GDP from the Gα subunit in the G-protein heterotrimer.
After GDP dissociation, GTP binds to the G in the G-protein heterotrimer causing its
dissociation into its active components of GGTP, G and its dissociation from the
receptor. Full agonists are maximally able to shift the equilibrium from R to R*, partial
agonists less so, and neutral antagonists do not affect this equilibrium. Inverse agonists,
however, stabilize the inactivated R state of the receptor, thereby reducing GDP/GTP
exchange. Additionally, constitutively active receptor spontaneously isomerizes from R
to R* in the absence of ligand (Seifert and Wenzel-Seifert 2002).
The ability of a cannabinoid ligand to act as a full, partial, or inverse agonist is
frequently measured as efficacy in [35S]GTPS binding assays. In these assays, a nonhydrolysable form of GTP, in which an oxygen on the  phosphate is replaced by a
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radioactive sulfur ([35S]GTPS), is incubated with cannabinoid ligands, excess GDP and
membrane homogenates containing the CB1 receptor and G-proteins. Receptor-activated
G releases GDP and binds [35S]GTPS, and the accumulation of this radioactive
complex is a measure of receptor-mediated G-protein activation in response to ligand.
Concentration effect curves for CB1-mediated G-protein activation are generated with
each ligand, and the Emax values of the curves are taken as measures of efficacy.
Examples of CB1 receptor high-efficacy, full agonists include WIN 55,212-2 (WIN) and
CP 55,940 (CP), CB1 partial agonists include 9-tetrahydrocannabinol (THC) and
methanandamide (MethA) and a CB1 receptor inverse agonist is SR141716A (Breivogel
et al. 1998; Breivogel and Childers 2000; Childers 2006). Efficacy of partial agonists can
also be shown indirectly by competitive antagonism; THC was first shown to be a partial
agonist when high concentrations of THC were shown to antagonize the full effects of
WIN when the two drugs were added together in a [35S]GTPS binding study in
cerebellar membranes (Sim et al. 1996).
G-proteins interact with the C-terminal tail of the CB1 receptor (Nie and Lewis
2001) and the third intracellular loop (Mukhopadhyay et al. 2000). Demonstrated
through the use of cannabinoid receptor intracellular domain mimicking peptides to
disrupt specific CB1 receptor-G-protein associations, inhibitory G-protein subtypes
interact specifically with certain regions of the CB1 receptor; Gi1 and Gi2 interact with
third cytosolic loop of the CB1 receptor (Mukhopadhyay et al. 2000; Mukhopadhyay and
Howlett 2001) and Gi3 and Go interact with the C-terminal tail (Mukhopadhyay et al.
2000). Furthermore, specific agonists have the ability to differentially activate specific
Gi proteins. CB1 receptors solubilized from membranes using detergent (3-[3(-
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cholamindopropyl) dimethylammonio] propanesulfonate, i.e. CHAPS) were coimmunoprecipitated with various types of G-proteins (Gi1, Gi2, Gi3) in the absence
of exogenously added cannabinoid ligands (Mukhopadhyay and Howlett 2005). Addition
of specific ligands caused the differential dissociation of the various types of G-proteins,
demonstrating ligand-specific G-protein activation. WIN stimulates all three Gi
subtypes, whereas desacetyllevonantradol (DALN) stimulates Gi1 and Gi2 while
acting as inverse agonist for Gi3, and MethA stimulates Gi3 while acting as an inverse
agonist for Gi1 and Gi2.

SR1 acts as an inverse agonist for all three subtypes

(Mukhopadhyay and Howlett 2005). The synthetic analog of THC, HU210, produces
maximal stimulation of both Gi and Go proteins, as measured by [35S]GTPS binding
assays of purified G proteins reconstituted with CB1 receptors recombinantly expressed
in Spodoptera frugiperda (Sf9) cells. WIN maximally activated Gαi but not Gαo. THC
caused only partial Gαi and Gαo activation (Glass and Northup 1999). Overall, this
evidence implies that different ligands can invoke various conformations of the CB1
receptor. Utilizing different ligands exogenously or the presence of CB1 receptorinteracting G-proteins endogenously could change the conformation of the CB1 receptor
to allow the promotion of differential signal transduction pathways. In theory, selective
pharmacological targeting of CB1 receptors could be used to promote therapeutic
pharmacological effects while minimizing unwanted side effects induced by the CB1
receptor, such as disruption of short-term memory and sedation (Mukhopadhyay et al.
2002). Moreover, if CB1 receptor G-protein coupling specificity is modulated by
endogenous proteins, then these proteins can also be pharmacologically targeted for the
same purpose.
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CB1 receptors are constitutively active (Bouaboula et al. 1997; Pan et al. 1998;
Nie and Lewis 2001), meaning that they can spontaneously shift conformation from R to
R* in the absence of ligand. This constitutive activity can increase basal G-protein
activity and modulation of effector system activity, and is reversible by inverse agonists
(Seifert and Wenzel-Seifert 2002). Lewis and Nie (2001) found that truncation of the
distal C-terminal tail of the CB1 receptor at amino acid 417 enhanced the constitutive
activity of the receptor. This raises the possibility that a protein binds to the distal Cterminal tail that attenuates the constitutive activity of the CB1 receptor.
A highly conserved aspartate in the second transmembrane domain, denoted
II:14D (transmembrane domain II, amino acid position 14, aspartate (D)) (Baldwin et al.
1997) or D164 (aspartate at CB1 amino acid position 164) is critical to CB1 receptor
constitutive activity. A mutation in this aspartate abolished constitutive activity without
disrupting agonist-mediated inhibition of Ca+2 channels (Nie and Lewis 2001) or
inhibition of cAMP production. However, disruption of this aspartate can disrupt the
coupling of the CB1 receptor to the potentiation of inward rectifying potassium channels,
and prevent the internalization of the receptor after exposure to agonist (Roche et al.
1999). When analyzing a GPCR for constitutive activity, determination of endogenous
ligands within the study system is important to rule out endogenous ligand-mediated
stimulation (Morisset et al. 2000). Furthermore, CB1 receptors are constitutively
internalized and recycled back to the cell surface, in a manner dependent on the
constitutive activity of the receptor (Leterrier et al. 2004; Leterrier et al. 2006), although
one group has suggested that constitutive activity may not be necessary for constitutive
internalization of CB1 receptors (McDonald et al. 2007).
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In addition, GPCRs coupled to inhibitory Gi/Go proteins are affected by sodium
concentrations (Jakobs 1979). Sodium stabilizes the inactivated R state of the receptor
and diminished basal G-protein activity, thus acting as an allosteric inverse agonist and
decreasing the apparent efficacy of inverse agonists (Koski et al. 1982) (Seifert and
Wenzel-Seifert 2002). Specifically, sodium has been shown to decrease CB1 receptor
agonist binding and G-protein interactions with the CB1 receptor (Devane et al. 1988;
Kuster et al. 1993; Houston and Howlett 1998). Additionally, an optimal sodium
concentration is required for the coupling of CB1 receptor to adenylyl cyclase inhibition
in specific brain regions, such as striatum. Interestingly, inhibition of adenylyl cyclase in
rat cerebellar second transmembrane spanning domain of GPCRs, II:14D, is responsible
for the allosteric regulation by sodium, which was first discovered via site-directed
mutagenesis of the 2-adrenergic receptor (Horstman et al. 1990) and has since been
demonstrated for a plethora of other GPCRs (Horstman et al. 1990; Kong et al. 1993;
Ceresa and Limbird 1994). The physiological sodium concentration at this aspartate is
unknown (Seifert and Wenzel-Seifert 2002).
Another hallmark of Gi/Go coupled receptor signaling is sensitivity to pertussis
toxin (PTX), derived from Bordetella pertussis (whopping cough). PTX ribosylates a
cysteine in the heterotrimeric forms of inhibitory Gi/o proteins (Locht and Antoine
1995), thus blocking all interaction with activated R* GPCRs (Seifert and Wenzel-Seifert
2002). PTX is used to confirm the involvement of inhibitory Gi/o proteins in CB1
receptor mediated downstream signals, including adenylyl cyclase inhibition (Howlett et
al. 1986; Pacheco et al. 1994) and N-type Ca+2current inhibition (Guo and Ikeda 2004).
CB1 receptor-mediated downstream signals not blocked by PTX do not involve inhibitory
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Gi/o proteins, rather they signal through alternative CB1-mediated pathways, possibly Gprotein-coupled receptor kinases (GRKs), -arrestin, PDZ domain-containing G-proteins
(Hall et al. 1999), or other G-proteins types, such as the signal switching to Gαs family
members seen when CB1 receptors are stimulated concurrently with dopamine (D2)
receptors (Glass and Felder 1997; Kearn et al. 2005).
Once activated, CB1 receptors modulate multiple downstream signaling events,
including inhibition of adenylyl cyclase (AC) (Howlett et al. 1986), phosphorylation of
p42/p44 mitogen activated protein kinases (MAPK), which are also known as
extracellular signal regulated kinases (ERK1/2) (Bouaboula et al. 1995; Derkinderen et
al. 2001; Galve-Roperh et al. 2002), inhibition of N-type and P/Q type voltage dependent
Ca+2 channels (Pan et al. 1996) (Twitchell et al. 1997), stimulation of inward rectifying
K+ channel (Mackie et al. 1995; Vasquez et al. 2003), inhibition of Na+ channels
(Nicholson et al. 2003), stimulation of phospholipases C and A2 (PLC, PLA2) (Hunter et
al. 1986), activation of c-Jun N-terminal kinase (JNK), and activation of p38 mitogenactivated protein kinase (Rueda et al. 2000). CB1 receptors generally inhibit AC (types 1,
3, 5, 6 and 8), but they also have the ability to stimulate certain AC isoforms (types 2, 4,
and 7) via G (Rhee et al. 1998).
The modulation of downstream signaling events by activated G-proteins is usually
accomplished through the G subunit (Clapham and Neer 1997; Offermanns 2003).
Such is the case for MAPK (Inglese et al. 1995), N and P/Q type voltage dependent Ca+2
channels (Herlitze et al. 1996), inwardly rectifying K+ channel (Logothetis et al. 1987),
and phospholipases C (Camps et al. 1992) and A2 (Jelsema and Axelrod 1987).
Adenylyl cyclase is regulated by both Gi and G, dependent on the subtype of AC; for
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the subtypes of AC inhibited by CB1 receptors (isoforms 1, 3, 5, 6 and 8) (Howlett et al.
2002), type 1 is inhibited by both Gi and G, whereas types 3, 5, 6 and 8 are inhibited
by Gi (Rhee et al. 2000; Offermanns 2003).
1.4 Cannabinoid Receptor Regulation & Cellular Localization
CB1 receptors signal are regulated in their native environments not only through
G-protein interactions, but also by modulation and trafficking of the receptors
themselves. Following agonist stimulation, CB1 receptors may be desensitized,
internalized and then recycled or downregulated, similarly to other GPCRs (Figure 4)
(Lefkowitz 1998). Ultimately these processes lead to a reduced CB1 receptor signal,
which could contribute to the development of tolerance (Maldonado 2002; Sim-Selley
and Martin 2002; Sim-Selley 2003).
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Figure 4. G-protein coupled receptor regulation and cellular location. Upon agonist
stimulation, G-protein receptor kinase (GRK) phosphorylates the GPCR, impairing the
ability of the receptor to interact with G-proteins. This process is known as
desensitization. Once phosphorylated, -arrestin can bind to the GPCR, stabilizing the
desensitized state and causing the receptor to internalize via clathrin-coated pits. Once
internalized, the GPCR is either degraded, otherwise known as downregulation, or
recycled back to the cell surface following dephosphorylation in acidified endosome.
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Upon agonist stimulation, CB1 receptors desensitize, making them less sensitive
to subsequent stimulation. Agonist binding causes a conformational change in the
receptor, activates G, which recruits G-protein coupled receptor kinases (GRKs)
(Pitcher et al. 1992), allowing G-protein coupled receptor kinase 3 (GRK3) (Hsieh et al.
1999; Jin et al. 1999) or G-protein coupled receptor kinase (GRK2) (Kouznetsova et al.
2002; Rubino et al. 2006) to phosphorylate serine 426 and/or 430 in the CB1 receptor Cterminal tail (Hsieh et al. 1999; Jin et al. 1999). GRK binding substantially impairs the
ability of the receptor to interact with G-proteins (Pitcher et al. 1998; Reiter and
Lefkowitz 2006). GRK phosphorylation recruits the binding of β-arrestin, which further
increases desensitization (Reiter and Lefkowitz 2006). CB1 receptor desensitization can
be seen as a decrease in the Emax of agonist stimulated [35S]GTPS binding in brain
membrane homogenates, (Sim et al. 1996; Sim-Selley and Martin 2002; Selley et al.
2004), and cannabinoid-stimulated [35S]GTPS autoradiography in brain slices (Sim et al.
1995; Sim et al. 1996), both of which measure GPCR-mediated G-protein activation.
THC treated rats (10 mg/kg/day, 21 days) subjected to [35S]GTPS binding and
autoradiography experiments show a decrease in WIN-stimulated binding in all brain
regions. However, the magnitude of desensitization varied by region, with the largest
decreases seen in hippocampus and cortex, followed by cerebellum, caudate-putamen,
globus pallidus, periaqueductal gray, and the smallest decrease in substantia nigra (Sim et
al. 1996). In addition, the time course required for desensitization varied by brain region;
hippocampus reached maximal desensitization follwing 7 days of THC treatment,
whereas cerebellum took 14 days to fully desensitize, and caudate-putamen required 21
days (Breivogel et al. 1999).
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CB1 receptor signal is further lost upon agonist binding when the desensitized
receptor is internalized into the cell interior (Hsieh et al. 1999; Coutts et al. 2001; Wu et
al. 2008). The CB1 receptor may then be degraded, a process termed downregulation,
and can be measured as decreased binding of radioactive cannabinoid ligands in
autoradiographic studies of brain slices (Oviedo et al. 1993; Breivogel et al. 1999; SimSelley and Martin 2002) or as decreased binding (Bmax values) in [3H]SR141716A
saturation binding analyses of brain tissue homogenates (Breivogel et al. 1999; SimSelley et al. 2006). The magnitude of CB1 receptor downregulation varies from brain
region to brain region; downregulation is greatest in cortex, cerebellum, hippocampus
and caudate-putamen, and less downregulation is seen for substantia nigra and globus
pallidus. (Rodriguez de Fonseca et al. 1994; Breivogel et al. 1999; Sim-Selley and Martin
2002). Downregulation in different brain regions is also time course dependent.
Maximal downregulation of CB1 receptors in the rat hippocampus and cerebellum was
achieved after 7 days of THC administration, but downregulation in the caudate/putamen
and globus pallidus was not detectable until 21 days (Breivogel et al. 1999).
The cause(s) of differential regional desensitization and downregulation of CB1
receptors in the CNS remains unknown, but may be caused by differential expression of
proteins that interact with the CB1 receptor, such as the region-specific expression of G7
(Watson et al. 1994), differences in the formation of CB1 receptor dimers from region to
region (Wager-Miller et al. 2002), differential changes in CB1 receptor mRNA levels in
response to chronic cannabinoid treatment (Zhuang et al. 1998; Romero et al. 1999; SimSelley et al. 2006) or variations in other unknown and uncharacterized proteins.
Additionally, proteins that are known to regulate CB1 receptor adaptation respond to drug

22
treatment; GRK2, GRK4, -arrestin 1 and -arrestin 2 are all upregulated by chronic
THC treatment (Rubino et al. 2006). These regulatory proteins may exhibit differential
regional localization and/or respond differently to chronic THC treatment in various brain
regions, and thus may account for differential CB1 receptor adaptation.
Downregulation occurs when, following GRK phosphorylation, -arrestin can
bind to the CB1 receptor, stabilizing desensitization and causing the receptor to
internalize via clathrin-coated pits (Reiter and Lefkowitz 2006). Once bound, -arrestin
associates with the AP-2 complex, the heterotetrameric clathrin adaptor protein that
targets the receptor to clathrin-coated pits (Laporte et al. 1999), and then binds directly to
clathrin to initiate internalization (Goodman et al. 1996). Specifically, CB1 receptors
have been shown to rapidly internalize in AtT20 cells via clathrin coated pits, because
sucrose pretreatment, which disrupts clathrin-coated pit formation (Heuser and Anderson
1989), prevented CB1 receptor internalization (Hsieh et al. 1999). Residues 460-463 for
the CB1 receptor are required for -arrestin-mediated internalization (Hsieh et al. 1999;
Daigle et al. 2008).
Alternatively, CB1 receptors can internalize into caveolae (Keren and Sarne 2003;
Bari et al. 2008; Wu et al. 2008), which are a specialized subclass of lipid rafts involved
in cholesterol trafficking, endocytosis of external molecules, and regulation of several
signal transduction pathways (Razani et al. 2002). CB1 receptors can co-localize with
caveolin-1, a major component of the caveolae protein coat (Bari et al. 2008).
Interestingly, when both clathrin-dependent and caveolae-dependent internalization were
blocked, CB1 receptors were still able to internalize, to a lesser extent, suggesting another
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endocyctic pathway remains to be discovered (Keren and Sarne 2003). An alternate
endocytic pathway may be flotillins, which are a clathrin and caveolin-independent
enodocytic pathway found in mammalian cells (Glebov et al. 2006)
Exposure time is an important factor in determining the fate of internalized CB1
receptors. Once internalized, CB1 receptors are either dephosphorylated, resensitized and
recycled back to the cell surface or targeted to the lysosomes for degradation
(downregulated) (Reiter and Lefkowitz 2006). Rapid recycling of the CB1 receptor
occurs after short agonist exposures, and requires dephosphorylation by an okadaic acidsensitive phosphatase and endosomal acidification. Resensitization of the receptors
occurs more rapidly for high (WIN) vs. low (THC) endocytotic agonists, suggesting the
CB1 receptor endocytosis is an important facilitator in the resensitization of CB1 receptors
(Bohn 2007; Wu et al. 2008). Long duration agonist exposure leads to downregulation
(Hsieh et al. 1999). In addition, shorter duration exposure to very high doses of CB1
agonists can also lead to downregulation (Keren and Sarne 2003; Martini et al. 2007).
G-protein-coupled receptor-associated sorting protein (GASP1) is responsible for
sorting the CB1 receptor into the downregulation pathway, increasing the associating
between CB1 receptors and lysosomal markers LAMP1 and LAMP2 (Martini et al. 2007).
WIN-induced CB1 receptor downregulation is attenuated by a dominant-negative mutant
of GASP1 (cGASP) in primary cultured rat spinal neurons. Additionally, the dominant
negative GASP1 mutant attenuated analgesic tolerance and CB1 receptor downregulation
in vivo following its injection into the spinal dorsal horn of mice expressed in a
recombinant chimeric adeno-associated virus 1/2 viron (Tappe-Theodor et al. 2007).
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Once downregulated, new protein synthesis is required for the recovery of the CB1
receptors to the cell surface (Hsieh et al. 1999).
The specific agonist used to desenstitize/downregulate the CB1 receptor is another
important factor in determining the fate of the CB1 receptor. For instance, THC, a low
endocytotic agonist exhibited greater desensitization than the high endocytic agonist
WIN, as measured by inhibition of intracellular cAMP accumulation (Wu et al. 2008).
Therefore, THC may robustly stimulate desensitization of CB1 receptors, while less
robustly inducing their internalization. Indeed, -arrestin 2 knockout mice show a
selective enhancement of THC-induced behavioral effects. -arrestin 2 knockout did not
affect sensitivity to other CB1 agonists tested, including CP, MethA, JWH-073 and O1812 (Breivogel et al. 2008). This finding suggests that THC-occupied CB1 receptors are
strongly influenced by -arrestin 2, possibly recruiting -arrestin 2 only or more strongly
than -arrestin 1, which may affect the processes of CB1 receptor desensitization and/or
downregulation.
Localization of the CB1 receptor within the plasma membrane itself may also be
important. Plasma membranes contain discrete regions of proteins and lipids, composed
largely of cholesterol and sphingolipds in the outer leaflet of the lipid bilayer, termed
lipid rafts (Barnett-Norris et al. 2005). Many GPCRs localize to the lipid rafts, and
agonist stimulation of these GPCRs can promote entry into, or exit from, the lipid raft
microenvironments (Patel et al. 2008). Importantly, many proteins associated with the
signaling of GPCRs, such as heterotrimeric G-proteins, may be targeted to lipid rafts due
to their lipid modifications, namely by the myrsotylation and/or palmitoylation of G
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subunits and prenylation of G subunits (Wedegaertner et al. 1995). Thus, lipid rafts
may aggregate GPCRs and their signaling proteins to increase the specificity and
efficiency of signal transduction (Moffett et al. 2000). Lipid rafts may also serve to limit
the signal transduction of CB1 receptors, because treatment of rat C6 glioma cells with
the lipid raft disruptor methyl--cyclodextrin (MCD) increases the stimulation of
[35S]GTPS binding by the endocannabinoid AEA and downstream signaling to AC and
p42/p44 MAPK (Bari et al. 2005). Thus exit or entry into lipid rafts via interactions with
agonists, or CB1 interacting proteins, could be important modifiers of CB1 receptor
activity.
1.5 Proteins that Interact with the CB1 Receptor
GPCRs do not interact exclusively with G-proteins. Rather, GPCRs exist in
tandem with numerous protein interacting partners, collectively termed a receptosome,
that control processes such as ligand specificity, signal amplification, constitutive
activity, GPCR localization, desensitization, internalization, recycling and
downregulation (for review see (Tilakaratne and Sexton 2005)).
In addition to Gi/Go proteins, the CB1 receptosome can contain numerous
proteins, including Factor Associated with Neutral sphingomyelinase activation (FAN),
involved in CB1-evoked sphingomyelin breakdown (Sanchez et al. 2001), Rab5 and Rab4
GTPases that regulate constitutive endocytosis and recycling, respectively, (Leterrier et
al. 2004), GRK2 (Kouznetsova et al. 2002) and GRK3 (Jin et al. 1999), which are
involved in CB1 receptor desensitization, -arrestin 2, which is involved in CB1 receptor
desensitization and internalization (Jin et al. 1999), and G-protein-coupled-receptorAssociated Sorting Protein (GASP1), which plays a role in CB1 receptor downregulation
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(Martini et al. 2007). This study will examine the function of the novel and as yet
relatively uncharacterized CB1 receptor interaction protein; Cannabinoid Receptor
Interacting Protein 1a (CRIP1a)
Like G-proteins, GRKs, -arrestin, and GASP1 discussed earlier, FAN interacts
directly with the CB1 receptor. The interaction of the CB1 receptor and FAN was
discovered after the observation that THC induces sphingomyelin breakdown in primary
astrocytes (Sanchez et al. 1998). FAN interacts directly with CB1 in primary astrocytes,
but not U373 MG astrocytoma cells, because FAN is immunoprecipitated from these
cells with anti-CB1 antibody. Interestingly, THC increased the binding of FAN to CB1
receptors, an effect that was blocked by SR1. Furthermore the role of FAN in CB1
receptor coupled sphingomyelin breakdown was confirmed using cells expressing a
dominant negative form of FAN, in which sphingomyelin breakdown was attenuated.
(Sanchez et al. 2001).
Contrariwise, Rab4 and Rab5 have not been shown to directly interact with the
CB1 receptor, but functionally colocalize with the receptor during receptor trafficking.
Rab GTPases organize membrane trafficking in eukaryotic cells and are associated with
the cell membrane by hydrophobic geranylgeranyl groups that are attached to one or two
carboxy-terminal cysteine(s). Specifically, Rab4 and Rab5 are involved in endosomal
fusion and endocytic recycling. (Stenmark 2009). Dominant negative (GDP-bound) and
dominant active (GTP bound) mutants of Rab4 and Rab5, but not Rab11, disrupt
constitutive endocytosis and recycling of the CB1 receptor, confirming their involvement
in these processes (Leterrier et al. 2004). Although they do not directly interact with the
receptor, these proteins may be considered part of the larger CB1 receptosome. This
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broad definition of receptosome could include other proteins that might be involved in
the signaling and regulation of the CB1 receptor, including proteins involved in
scaffolding, signal modulation or other GPCRs (e.g. CB1-GPCR heterodimers), and are
too numerous for discussion here.
A common protein-protein interaction motif between GPCR interacting proteins
is the PDZ domain. The acronym „PDZ‟ is derived from the first three proteins in which
these motifs were identified (PSD-95, Disc large protein and ZO-1) (Tilakaratne and
Sexton 2005). The vast majority of PDZ-containing proteins are associated with the
plasma membrane. In addition, multiple copies of the PDZ domains commonly occur
within a single polypeptide chain (Jelen et al. 2003). These ubiquitous protein interaction
modules are commonly found in proteins involved in receptor trafficking, receptor
anchoring/stabilization, scaffolding for assembly of signaling molecules, and modulation
of receptor ligand specificity (Tilakaratne and Sexton 2005). An example of a PDZ
containing protein is spinophilin, which contains one PDZ domain and is known to
interact with the D2 dopamine receptor (Smith et al. 1999). In addition, spinophilin is
known to interact with other protein binding partners, including other GPCRs,
cytoskeletal and cell adhesion molecules, ion channels and enzymes. The function of
spinophilin has not been fully elucidated, but is proposed to provide a link between
GPCRs and mitogenic signaling events, as well as regulate synaptic plasticity, spine
morphology, and neuronal migration (Sarrouilhe et al. 2006).
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1.6 Cannabinoid Receptor Interacting protein (CRIP1a)
The discovery that the truncation of the distal C-terminal tail of the CB1 receptor
enhanced the constitutive activity of the CB1 receptor (Nie and Lewis 2001) lead to a
search for a protein that binds to the CB1 receptor C-terminus and inhibits the constitutive
activity of the CB1 receptor. Two novel proteins, coined cannabinoid receptor interacting
proteins, (CRIP1a & CRIP1b) were recently discovered via yeast two-hybrid screening of a
human brain cDNA library using the last 55 amino acids of the C-terminal tail of the CB1
receptor (amino acids 418-472) as bait (Niehaus et al. 2007).
A CB1 receptor interacting gene was found on human chromosome 22 that
alternatively splices to form CRIP1a (exons 1, 2 and 3a) and CRIP1b (exons 1, 2, and 3b),
which are 164 and 128 amino acids, respectively. The GenBank accession numbers for
the nucleotide sequences of CRIP1a and CRIP1b are AY883936 and AY144596,
respectively. The role of CRIP1b is unclear; it is found only in primates and its effects on
CB1 receptor function remain undiscovered. However, CRIP1a appears to decrease the
constitutive activity of the CB1 receptor.
The region of the CB1 receptor required for CRIP interaction was determined
using a yeast two-hybrid screening of various CB1 receptor C-terminal tail mutants as
bait and CRIP1b as prey (Figure 6). The last nine amino acids of the CB1 receptor were
required for CRIP1b interaction. CRIP did not interact with either the desensitization (aa
419-438) or internalization (aa 460-463) regions of the CB1 receptor. Furthermore,
Western blot analysis of in vitro binding assays confirmed CRIP1a/CB1 interaction, as
bacterially expressed CRIP1a bound specifically to immobilized GST-CB1 C-terminal tail
and not to the negative control, GST.
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In vivo interaction of CRIP1a and the CB1 receptor was confirmed using coimmunoprecipitation of CRIP1a with the CB1 receptor from rat brain homogenates.
CRIP1a was highly expressed in mouse brain homogenates, and also detectable in heart,
lung and intestine via Western blot analysis, as well as in mouse brain and cerebellar
homogenates. Confocal microscopy of cDNA microinjected rat superior cervical
ganglion (SCG) neurons found that CRIP1a, CRIP1b and the CB1 receptor are enriched
near the plasma membrane and overlap in orthogonal perspectives.
Comparative genomic analyses indicate that CRIP1a is conserved throughout the
vertebrates. CRIP1a contains no transmembrane domains, as determined by hydropathy
analysis, but does contain a predicted palmyitoylation site, which may aid its association
with the plasma membrane. The C-terminal tail of CRIP1a contains a predicted PDZ
Class I ligand, which could allow it to interact with PDZ-containing G-proteins. This
finding suggests that CRIP1a, like many other proteins that interact with PDZ modules,
may be important for regulating GPCR signaling, scaffolding or trafficking.
Electrophysiological voltage-step protocol of calcium current recordings in rat
SCG neurons microinjected with cDNA encoding the CB1 receptor, with and without comicroinjection of cDNA encoding CRIP1a, showed that CRIP1a attenuated the constitutive
CB1-mediated inhibition of calcium channels, as revealed by an elimination of the inverse
agonist activity of SR1 (Figure 7) . However, the CB1-receptor mediated decrease in
calcium current elicited by the CB1 agonist WIN was unaffected by co-expression of
CRIP1a (Niehaus et al. 2007).
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Figure 6. CB1 receptor interaction with CRIP requires the last nine amino acids of the
CB1 C-terminal tail. Desensitization (D) and internalization (I) regions of the CB1
receptor are depicted as boxes. Numbers indicate the amino acids residues of the rat (r)
CB1 receptor used as bait in yeast two-hybrid screening. Reprinted from Niehaus et al.
(2007).
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Only one other study has examined CRIP1a; Ludanyi et. al. (2008) postulated that
endocannabinoid signaling has an important protective role against pathologic neuronal
excitability. To address this hypothesis, they utilized quantitative PCR measurements to
evaluate mRNA levels of CB1 receptor related molecular elements in epileptic versus
healthy postmortem human hippocampal tissue. Human sclerotic hippocampi show a
reduction in CRIP1a gene expression in tandem with reduction in CB1 receptor
expression, suggesting that downregulation of the CB 1 receptor, in tandem with CRIP1a
may facilitate the harmful effects of increased neuronal excitability (Ludanyi et al. 2008).
The known effects of CRIP1a on activity modulated by the CB1 receptor are
limited (Table 1). According to Neihaus et al. (2007), CRIP1a does not affect CB1
receptor expression, but does inhibit the constitutive inhibition of Ca+2 channels by the
CB1 receptor without affecting agonist-induced inhibition of this effector. This
dissertation further examines the effect of CRIP1a on constitutive and agonist-mediated
CB1 receptor function using human embryonic kidney (HEK) cells stably transfected
with the human CB1 (hCB1 HEK) compared to cells containing a stable co-transfection of
CRIP1a (hCB1-HEK CRIP1a). Several CRIP1a effects will be examined (Figure 8),
including effects of CRIP1a on ligand specific CB1-receptor mediated G-protein
activation, constitutive activity of the CB1 receptor, CB1 receptor desensitization and
downregulation, downstream signaling events, and cell type specificity of effects. In
addition, the stoichiometric relationship of CRIP1a to the CB1 receptor in cell and animal
models will be examined.
I hypothesize that CRIP1a will attenuate constitutive CB1 receptor-mediated Gprotein activation, thus explaining the effects on downstream signaling by Neihaus et al.
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(2007). In addition, I expect to see a similar inhibition of CB1 receptor constitutive
activity on other downstream signaling events, including the constitutive inhibition of
adenylyl cylase and constitutive phosphorylation of ERK 1/2. However, I do not expect
CRIP1a to modulate ligand stimulated effects of the CB1 receptor at the G-protein or at
the downstream effector level. Additionally, because CRIP1a binds to the C-terminal tail
of the CB1 receptor, where proteins that affect CB1 receptor trafficking also bind, it is
possible that CRIP1a will modulate ligand-induced desensitization and downregulation of
the CB1 receptor. However, as the CRIP1a binding site does not directly overlap with the
CB1 C-terminal tail region specifically required for desensitization or downregulation,
there may be no effect. In addition, I expect CRIP1a to be upregulated in response to
chronic cannabinoid administration in the whole animal, as seen with other CB1 receptor
interacting proteins such as GRKs and β-arrestins. My overall hypothesis is that CRIP1a
is the member of the CB1 receptosome that determines the constitutive activation of the
CB1 receptor.
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Figure 7. CRIP1a decreases CB1 receptor-mediated tonic inhibition of voltage-gated Ca+2
channels. Panel a, top, voltage-step protocol used to elicit Ca+2 current. Bottom,
superimposed Ca+2 current traces perfusion of control solution (middle trace), 1 M WIN
(top trace) or 1 M SR1 (bottom trace) for a representative SCG neuron expressing CB1
receptor. Panel b. Ca+2 current amplitude from a SCG neuron expressing CB1 receptor
plotted over time course of a representative experiment. Application of the CB1 agonist
WIN decreased Ca+2 current, whereas the CB1 inverse agonist increased Ca+2 current.
Panel c. top, voltage step protocol used to elicit Ca+2 current traces during perfusion of
control solution (middle trace), WIN (top trace) or SR1 (bottom trace) for a
representative neuron co-expressing CB1 receptor and CRIP1a. Panel d. Ca+2 current
amplitude from a SCG neuron co-expressing CB1 and CRIP1a plotted over the time
course for a representative experiment. Application of the CB1 agonist WIN decreased
Ca+2 current; however, the ability of the CB1 agonist to increase Ca+2 current was
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impaired. Panel e, the ability of the CB1 agonist WIN to inhibit Ca+2 current is
unaffected by CRIP1a. Panel f, CB1-mediated enhancement of Ca+2 current by inverse
agonist SR1 is significantly attenuated by CRIP1a (* p < 0.05). Scale bars in panels a and
c, 500 pA, 25 ms.
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Figure 8. CRIP1a effects to be examined in this dissertation. This study will address the
effects of CRIP1a on the constitutive activity of the CB1 receptor, on acute ligand-specific
effects on CB1 receptor mediated G-protein activation, on CB1 receptor desensitization
and downregulation in response to prolonged agonist treatment, and on CB1 receptor
downstream signaling to effectors. Additionally, this study will examine the
stoichiometric relationship between CRIP1a and the CB1 receptor in CB1 receptor
expressing cells and rat cerebellum.
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CRIP1a Effects?
CB1 Receptor
Expression
G-protein Activation
Receptor
Desensitization
Receptor
Downregulation
Ca+2 Channel
Inhibition
Adenylyl Cyclase
Inhibition
ERK 1/2

Constitutive
No (1)

Agonist-Mediated
None apparent.

?
None apparent.

?
?

None apparent.

?

Yes (1)

No (1)

?

?

?

?

Table 1. Summary of the effects of CRIP1a on CB1 receptor modulated activity. Prior to
this dissertation, known effects of CRIP1a are listed. References: (1) Neihaus et al.
(2007).
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Chapter 2. Methodology
2.1 Chemicals.
[35S]GTPS (1150-1300 Ci/mmol) was obtained from PerkineElmer Life and
Analytical Sciences (Whaltman, MA). [3H]SR141716A (44.0 Ci/mmol) was purchased
from GE Healthcare (Buckinghamshire, UK). WIN 55,212-2 (dissolved in ethanol),
GDP (H2O), pertussis toxin (H2O) and bovine serum albumin (BSA) were purchased
from Sigma-Aldrich (St. Louis, MO). THC (ethanol), CP 55,940 (ethanol), and
SR141716A (ethanol) were provided by the Drug Supply Program of the National
Institute of Drug Abuse (NIDA, Rockville, MD). Methananamide (ethanol) was
purchased from Cayman Chemical (Ann Arbor, MI). Levonanatradol (ethanol), HU210
(H2O) and Noladin Ether (ethanol) were supplied by the Department of Pharmacology &
Toxicology (Virginia Commonwealth University, Richmond, VA) via the NIDA Drug
Supply Program. GST-tagged CRIP1a construct in pGEX vector was provided by Dr.
Kathleen Wallis (Medical College of Georgia, GA). CRIP1a antisera 077.4 was provided
by Dr. Maurice Elphick (Queen Mary, University of London). Licor Odyssey infrared
dye secondary antibodies were purchased from Li-Cor Biosciences (Lincoln, NE).
Alpha-tubulin antibody and phosphorylated ERK 1/2 antibody was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). ERK 1 antibody was purchased from Chemicon
(Billerica, MA). All other reagent grade chemicals were purchased from Sigma-Aldrich
(St. Louis, MO).
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2.2 Cell culture.
Human embryonic kidney (HEK 293) cells stably expressing the human CB1
receptor (hCB1-HEK) were cultured in Dulbecco‟s Modified Eagle Medium, 1x high
glucose (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
(P/S), 0.25 mg/ml Geneticin (G418) and 15mM HEPES. hCB1-HEK cells stably cotransfected with CRIP1a (hCB1-HEK-CRIP1a) were cultured in the same media with the
addition of 0.1 mg/ml zeocin. Both cell lines were provided by Dr. Deborah Lewis
(formerly of the Medical College of Georgia). Dr. Mary Abood (Temple University)
created the hCB1-HEK cell line.
Chinese hamster ovary (CHO) cells stably expressing the mouse CB1 receptor
(mCB1-CHO) were cultured in Dulbecco‟s Modified Eagle Medium: Nutrient Mixture F12 (DMEM/F12) containing 10% FBS, 1% P/S, and 0.25 mg/ml Hygromycin B. mCB1CHO stably co-transfected with CRIP1a (CB1-CHO-CRIP1a) were cultured in the same
media with the addition of 1 mg/ml G418. mCB1-CHO cells were provided by Dr. Billy
R. Martin (Virginia Commonwealth University).
2.3 Cell Culture Drug Treatment
Cells were grown to greater than 95% confluency, except where otherwise
indicated. Appropriate concentrations of drugs were added to drug treatment media
(DMEM, 1% FBS, 1% P/S) and sterile filtered. Drug treatment media was added to cells
and incubated for the appropriate time period. To terminate drug treatments, cells were
rinsed twice for 2 min with warm rinse media (DMEM, 1% FBS), and harvested, as in
section 2.5, for use in assay.

39

2.4 Cell Transfection
Cells were transfected at 50-80% confluency. Plasmid DNA was added to
DMEM media and Plus Reagent (Invitrogen) in the following ratio: per 1 g DNA, use
60 l DMEM and 10 l Plus reagent, and incubated at room temperature (RT) for 15
min. DNA/Plus Reagent mixture was then combined with an equal volume mixture of
Lipofectamine (Invitrogen) in the ratio of 2.5 l Lipofectamine per 1 g DNA and
incubated for 15 min at RT. Cells were rinsed 2x with DMEM, and covered with DMEM
at the transfection medium volume recommended by the manufacturer (Invitrogen). The
DNA complex was added and the cells incubated for 4-6 hours. Media were removed
and replaced with complete culture media specific to the untransfected cell type.
Transiently transfected cells were harvested and used after 48 hours.
For stable CRIP1a cell transfection, cells were trypsinized and incubated with
increasing doses of selection antibiotic known as a „kill curve‟. After one week, the
concentration of selection antibiotic in which the cells were 50% confluent was the
concentration used for all complete cell media preparations. The 50% confluent cells
were grown to 100% confluency. Cells were typsinized and plated in 96-well plates at a
density of 1 cell for every 3 wells, insuring that each colony was grown from a single
cell. Each week the colonies with surviving cells were moved into larger plates (24 well
plate, 6 well plate, 10 cm dish). The colonies were then harvested and stored for use in
assays. Cells were screened via immunoblot (see section 2.8) for CRIP1a expression and
[3H]SR141716A saturation analysis (see section 2.9) for CB1 receptor expression. The
colony in which CRIP1a expression was the highest and had a CB1 receptor level most
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similar to the CB1-CHO cells without CRIP1a transfection was selected and cultured for
future experiments.
2.5 Membrane Homogenate Preparation.
Cells were harvested in PBS + 0.4% (w, v) EDTA or scraped and centrifuged at
1000 x g for 10 min to remove media. Cells were homogenized in ice-cold assay buffer
(50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM, pH 7.4), centrifuged at
50,000 g for 10 min, and protein content was determined by the Bradford method
(Bradford 1976).
2.6 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry
(LC-ESI-MS-MS) Analysis of Endocannabinoids.
The endocannabinoids, arachidonoyl ethanolamide (AEA) and 2-arachidonoyl
glycerol (2-AG) were measured using a method modified from Di Marzo et al. (Di Marzo
et al. 2000). Briefly, 1 nmol of AEA-d8 and 2 nmol 2AG-d8 as deuterated internal
standards were added to each sample. The endocannabinoids were extracted from the
samples with 3 volumes chloroform/methanol (2/1, v,v) and a 0.73% (w,v) sodium
chloride mixture. The chloroform was collected and evaporated to dryness with nitrogen.
The extracts were reconstituted with 100 L methanol and placed in autosample vials for
LC-ESI-MS-MS analysis. The AEA and 2-AG were separated and detected using a
Shumadzu SCL HPLC system (Kyoto, Japan) with a Discovery® HS C18 Column 15cm
x 2.1mm, 3m (Supelco: Bellefonte, PA) kept at 40°C and an Applied Bio systems 3200
Q trap with a turbo V source for TurbolonSpray (Ontario, Canada) run in multiple
reaction monitoring (MRM) mode. The mobile phase was 10 % water with 1g/L
ammonium acetate and 0.1% (v,v) formic acid, and 90% (v,v) methanol with 1 g/L
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ammonium acetate and 0.1% (v,v) formic acid

The flow rate was 0.3 mL/min and total

run time was 10.00 min. The injection volume was 20 L and the auto sampler
temperature was set at 5°C. The following transition ions for AEA, AEA-d8, 2-AG and
2-AG-d8 were monitored: 348 > 62, 356 > 62, 387 > 96 and 379 > 287 m/z, respectively.
The standard curves for the samples were 0.039 – 1.25 pmol AEA and 0.063- 2.0 nmol 2AG. The limit of detection and limit of quantification were set at 0.039 pmol for AEA
and 0.063 nmol for 2-AG.
2.7 CRIP1a Generation, Purification, and Determination of Stoichiometry.
Glutathione-S-transferase (GST)-tagged CRIP1a vector (GST tag-thrombin
cleavage site-CRIP1a) was provided in pGEX-4T-1 vector (GE Healthcare, Piscataway,
NJ), cloned into the BAM HI and XHO sites of the vector. Plasmid DNA containing
GST-tagged CRIP1a was transformed into E. coli BL21-DE3 competent cells. E. coli
were grown to OD(600) = 0.6 from a single colony, and then GST-tagged CRIP1a
expression was induced via addition of isopropyl thiogalactoside (IPTG, 1 mM) for 6
hours. E. coli were collected via centrifugation (1,000 g, 10 min, 4 C) and a bacterial
lysate produced via sonication with lysozyme (25 µg/ml). CRIP1a induction and
solubility tests were performed by polyacrylamide gel electrophoresis (PAGE) on harvest
lysates (crude lysate, which was then separated into soluable and insoluable lysates) on
10% polyacrlamide gels and stained with Coomassie blue to verify protein expression.
GST-tagged CRIP1a was isolated from bacterial lysate using a GSTrap FF column
(Amersham Biosciences, Piscataway, NJ) according to the manufacturer‟s instruction.
Briefly, the column was equilibrated with binding buffer (0.1 M phosphate buffered
saline, PBS), bacterial lysate was added to allow GST-CRIP fusion, the column was
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washed (PBS), and the GST tag was cleaved via thrombin (500 units in 0.5 ml PBS).
Following elution with PBS, the eluate contained protein and thrombin. The thrombin
was subsequently removed by HiTrap Benzamidine column purification according the
manufacturer‟s instruction. Briefly, the column was equilibrated with binding buffer
(0.05 M Tris-HCl, 0.5 M NaCl, pH 7.4). Sample was added to the column and eluted
with binding buffer. Eluates were collected and pooled. CRIP1a pools and a BSA protein
concentration curve were subject to PAGE using 15% polyacrylamide gels, and
visualized by Coomassie blue stain. Stained gel images were captured via ImageJ, and
CRIP1a concentration was determined by subsequent linear regression analysis (Windows
Excel). CRIP1a concentration curves were then generated in tandem with hCB1-HEK (
CRIP1a) or mCB1-CHO ( CRIP1a) cell membrane preparations or mouse cerebellum to
determine CRIP1a concentration via immunoblot analysis on 15% polyacrylamide gels,
visualized by the Licor Odyssey system. From this data, the relationship between CRIP1a
concentration in the cells and CB1 receptor levels, determined by [3H]SR141716A
saturation binding, was calculated.
2.8 Mouse THC Treatment
Male ICR mice were housed in an animal care facility maintained at 22  2 C on
a 12 hour light/dark cycle. Food and water were available ad libitum. All experiments
were conducted according to the guidelines established by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University Medical Center. THC was
dissolved in a 1:1:18 solution of ethanol, castor oil 40 mole ethoxylate (Emulphor) and
saline. Mice received subcutaneous injections of THC or vehicle twice daily (7:00 am
and 3:00 pm) for 6.5 days. Mice were injected with 10 mg/kg THC that was increased
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every other day to 30 and 60 mg/kg THC, respectively. Twenty-four hours after final
injection, mice were sacrificed and decapitated. Hippocampi were harvested from brains
and were immediately frozen in isopentane at -30 C and stored at -80 C.
2.9 Immunoblotting.
Samples (70 g) of cell membrane homogenates were added to sample buffer (1
M TRIS, 20% SDS, 1 M DTT, 60% sucrose, bromophenol blue) and boiled for 10 min.
Samples were loaded into 15% SDS polyacrylamide gels, and electrophoresis was
conducted at 120 V for 1.5 hours. Proteins were electrophorectically transferred to
polyvinylidene difluoride (PVDF) membranes at 70 V for 70 min. Blots were blocked
for 1 hour at room temperature (RT) with 5% (w/v) nonfat dry milk and then rinsed with
TRIS buffered saline with 0.1% (v/v) Tween-20 (TBST). Primary antibody (anti-CRIP1a
antisera 077.4 (rabbit), 1:500) was incubated overnight at 4 C, followed by TBST rinse.
Secondary antibody (Licor goat anti-rabbit 800 CW IR dye, 1:5,000) was then incubated
at RT for 1 hr, followed by TBST rinse. Blots were visualized with the Licor Odyssey
system.
2.10 [3H]SR141716A Binding.
Saturation analysis of [3H]SR141716A ([3H]SR1) binding was performed by
incubating 30 g of membrane protein with 0.5-10 nM [3H]SR1 in TME (50 mM TRIS, 3
mM MgCl2, 0.2 mM EGTA) with 0.5% (w/v) BSA, in a total volume of 0.5 ml  5 M
unlabeled SR1 to determine non-specific binding. The assay was incubated for 90 min at
30 C and terminated by vacuum filtration through GF/B glass fiber filters that were
presoaked in Tris buffer containing 0.5% (w/v) BSA. Bound radioactivity was
determined using liquid scintillation spectrophotometry at 45% efficiency for [3H].
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2.11 [35S]GTPS Binding.
Cell membrane preparations (10 g protein) were incubated with various drugs,
100 mM NaCl, 0.1 % BSA, 10 M GDP and 0.1 nM [35S]GTPS in TME, 0.5 ml total
volume, for 2 hr at 30 C. In some experiments, 100 mM NaCl was replaced by varying
concentrations of NaCl. Basal binding was assessed in the absence of agonist, and
nonspecific binding was measured with 10 M unlabeled GTPS. The reaction was
terminated by vacuum filtration through GF/B glass fiber filters. Bound radioactivity
was determined by liquid scintillation spectrophotometry at 95% efficiency for [35S].
2.12 [3H]cAMP Whole Cell Assay
Cells were seeded on 24-well plates the previous evening to reach 100%
confluency on day of assay. Cells were treated with phosphodiesterase inhibitor mix (1
M HEPES, 10 mM RO 20-1724, 100 mM IBMX, 100 mg/ml BSA in DMEM) for 30 min
at 37 C. Cells were then incubated in the presence of 10 µM forskolin, with and without
drugs, for 8 min, in a total reaction volume of 200 µl. Following drug treatment, cells
were placed on ice and drug-containing media removed to terminate the reaction. Cells
were lysed with 3% perchloric acid for 30 min, and neutralized with 15% potassium
bicarbonate.
Cell lysate supernatant was assayed for cAMP formation using the Liquid Phase
Cyclic AMP radioassay (Diagnostic Products Corporation), which determines cAMP
concentration through competitive displacement of labeled versus unlabeled cAMP
binding to a cAMP binding protein, according to the manufacturer‟s instruction. Briefly,
cell supernatant or cAMP standards are combined with [3H]cAMP and cAMP binding
protein in a TRIS-EDTA buffer and incubated on ice for 90 min. A blank (no cells), cell
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blank (with cells), and total binding were assayed in the absence of cAMP binding
protein. Unbound cAMP was removed through the addition and subsequent
centrifugation (15,000 g, 10 min, 4 C) of 100 ml of a charcoal/dextran suspension.
Radioactivity of the supernatant was determined using liquid scintillation
spectrophotometry at 45% efficiency for [3H]. A log transformation calibration curve of
radioactivity versus standards was generated on Microsoft Excel from which unknown
cAMP concentrations were determined.
2.13 MAP Kinase Assay
Cells were seeded on 6 well plates the previous evening to reach 100%
confluency on the day of assay. Cells were serum starved (no FBS) for 6 hours prior to
drug treatment. Cells were then incubated for 8 min with either WIN (2 µM), THC (3
µM), SR1 (0.2 µM) or vehicle in a reaction volume of 1 ml. Following drug treatment,
cells were placed on ice to terminate the reaction and treated with 200 µl cell lysis buffer
(0.5% NP40, 1% Triton X-100, 20 mM Tris-HCl, 135 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM NaF, 1 mM PMSF, 1 mM Na Vandate, and 1:1000 aprotonin) for 15 min.
Cell lysates were centrifuged for 15 min at 13,000 rpm at 4 C. The protein
concentration of the resultant membrane preparations was determined via Bradford assay.
Membrane preparations were subject to immunblot analysis of pERK 1/2 and ERK 1/2
levels as described in Methods 2.9. Membrane preparations of hCB1-HEK cells
(CRIP1a transfection) (50 g) were probed using phosphorylated ERK 1/2 antibody
(1:200 Santa Cruz) and ERK 1 antibody for loading control (1:250, Chemicon).
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2.14 Data Analysis.
Unless otherwise noted, all binding data are reported as mean values ± standard
error of the mean (SEM) of at least three independent experiments that were each
performed in duplicate ([3H]SR141716A) or triplicate ([35S]GTPS). Data were analyzed
using Graph Pad Prism v4.0c software. Bmax, KD, Emax and EC50, values were determined
by non-linear regression analysis. Non-linear regression was used to fit the data to the
following equation: y = (Bmax)(L)/(KD + L) where y is equal to the amount of
[3H]SR141716A or [35S]GTPS bound at receptor ligand concentration L. Emax and EC50
was substituted for Bmax and KD respectively where appropriate. Bmax and Emax is the
amount of [3H]SR141716A and [35S]GTPS bound at maximally effective concentrations
of receptor ligand, respectively. KD and EC50 values are the concentration of receptor
ligand producing half maximal binding of [3H]SR141716A and modulation of
[35S]GTPS binding, respectively. Basal binding is determined in the absence of ligand.
Net stimulated binding is defined as agonist-stimulated minus basal binding. Percentage
of stimulation is defined as (net stimulated binding/basal binding) x 100%.
Measurements of cAMP levels and MAPK activity were the results of at least 3
independent experiments. cAMP levels were measured in duplicate in each experiment.
Data are reported as percentage of control, which is defined as (ligand modulated
value/vehicle value) x 100%.
Significance was determined using ANOVA and the post-hoc Newman-Keuls
Multiple Comparison Test for comparison of three or more conditions or by students ttest for comparison of two conditions. Two way ANOVA and the post-hoc Bonferroni
Test was used in experiments examining the effects of CRIP1a on CB1 receptor function
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in conjunction with NaCl effects, and on CB1 receptor desensitization. Results were
considered statistically significant when the p value ≤ 0.05.
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Chapter 3. Results

3.1 CB1 Receptor Expression in hCB1 HEK, hCB1 HEK-CRIP1a Cell Lines and Rat
Cerebellum.
Previous studies have shown that CRIP1a localizes to the cell membrane and
interacts with the C-terminal tail of CB1 receptors, without affecting CB1 receptor
expression levels (see Introduction 1.6). Initial experiments were performed to confirm
that lack of effect of CRIP1a on CB1 receptor levels. Human embryonic kidney cells
(HEK) stably transfected with the human CB1 receptor (hCB1-HEK) cells were created
by Dr. Mary Abood (Temple University). hCB1-HEK with a stable co-transfection of
CRIP1a (hCB1-HEK-CRIP1a) were co-transfected and provided by Dr. Deborah Lewis
(formerly of the Medical College of Georgia).
To determine whether the stable co-expression of CRIP1a affected CB1 receptor
expression levels, [3H]SR141716A saturation binding analyses were performed in hCB1HEK and hCB1-HEK-CRIP1a cells (Table 2). There were no statistically significant
differences between hCB1-HEK, with and without CRIP1a co-expression with regard to
CB1 receptor number (Bmax = 1.64  0.29 pmol/mg in cells without CRIP1a versus 1.51 
0.30 pmol/mg in cells with CRIP1a) or the equilibrium dissociation constant, (KD = 3.02 
1.59 nM in cells without CRIP1a versus 3.82  1.34 nM in cells with CRIP1a), according
to students t-test (signficance reached at p < 0.05).
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Bmax

KD

(pmol/mg)

(nM)

hCB1-HEK

1.64  0.298

3.02 ± 1.59

hCB1-HEK-CRIP1a

1.51  0.308

3.82 ± 1.34

Rat Cerebellum

3.63 ± 0.372

0.452 ± .077

Table 2. [3H]SR141716A saturation analysis of hCB1-HEK cells, with and without
CRIP1a co-expression, and rat cerebellum. Data are mean values  SEM (n=6). Bmax
values represent total cell membrane receptor levels. No significant differences between
the two hCB1-HEK cell types were observed. KD values represent the reciprocal of the
affinity of [3H]SR141716A for the receptor. No significant effect of CRIP1a on the
affinity of [3H]SR141716A binding was observed.
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In addition, CB1 expression levels were determined in rat cerebellum, for later
stoichiometric comparison to the hCB1-HEK ( CRIP1a) cell lines. Rat cerebellum
expressed CB1 receptors at a Bmax value of 3.63 ± 0.372 pmol/mg.
3.2 CB1 Receptor Expression Relative to Cell Confluency in hCB1-HEK ( CRIP1a)
Cell Lines.
The level of cell confluency can affect the expression level of cell surface
receptors, which might be modulated by CRIP1a. To determine whether cell confluency
affected the expression of stably transfected CB1 receptor in the hCB1-HEK ( CRIP1a)
cell lines, cells were grown to low (50%), high (95%), and ultra-confluence (100+ %) and
assayed for CB1 receptor expression using saturation analysis of [3H]SR141716A binding
(Figure 9). High and ultra-confluence did not affect CB1 receptor expression in hCB1HEK with and without CRIP1a transfection. However, low confluency significantly
decreased CB 1 receptor expression in hCB1-HEK cells compared to hCB1-HEK-CRIP1a
cells (ANOVA, Newman Keuls Multiple Comparison post-hoc test). hCB1-HEK cells at
50% confluency expressed a Bmax value of 0.90  0.29 pmol/mg compared to a Bmax
value of 1.43  0.29 and 1.64  0.29 pmol/mg for high and ultra-confluency, respectively.
Low confluency did not affect CB1 receptor expression in hCB1-HEK-CRIP1a cells, with
a Bmax value of 1.68 ± 0.17 pmol/mg compared to 1.63  0.26 and 1.51  0.30 pmol/mg
for high and ultra-confluency, respectively. In all subsequent radioligand binding
experiments, cells were harvested and utilized at a greater than 95% confluence.
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Figure 9. CB1 receptor expression relative to cell confluency in hCB1-HEK cells
(CRIP1a co-expression). Data are mean Bmax values from saturation analysis of
[3H]SR141716A binding  SEM (n=4). hCB1-HEK cells (CRIP1a transfection) were
grown to low (50%), high (95%) and ultra-confluence (100+%) and subject to
[3H]SR141716A. High and ultra confluence did not affect CB1 receptor expression in
hCB1-HEK cells (CRIP1a transfection). Low confluency significantly decreased CB1
receptor expression in hCB1-HEK cells compared to hCB1-HEK-CRIP1a cells. (ANOVA,
Newman Keuls Multiple Comparison post-hoc test, p < 0.05).
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3.3 CRIP1a Expression and Stoichiometric Relationship of CRIP1a/CB1 in hCB1
HEK Cell Lines ( CRIP1a co-transfection) and Mouse Cerebellum.
The effect of CRIP1a on CB1 receptor function is likely to be determined in part
by the molar ratio of CRIP1a to CB1 receptor. To determine the stoichiometric
relationship of the CRIP1a to CB1 receptor, CRIP1a was generated and purified using
GST-pulldown methodology. Purified CRIP1a was used to generate CRIP1a concentration
curves. hCB1-HEK ( CRIP1a) membrane preparations (70 g) were compared to CRIP1a
concentrations curves via immunoblot of 15% polyacrylamide gels and visualized by the
Licor Odyssey system to elucidate unknown CRIP1a concentrations (Figure 10). CRIP1a
concentrations were determined for male mouse cerebellum in the same manner.
Experimentally determined CRIP1a concentrations were compared to CB1 receptor
expression (Table 2) to determine the molar stoichiometric relationship of CRIP1a/CB1
receptors (Table 3). In hCB1-HEK cells lacking CRIP1a transfection, the molar ratio of
CRIP1a/CB1 is less than 1 (0.376  0.875), indicating that the CB1 receptor is in molar
excess relative to amount of CRIP1a natively expressed in hCB1-HEK cells. In hCB1HEK-CRIP1a cells, CRIP1a is in molar excess to the CB1 receptor, with a molar ratio of
CRIP1a/CB1 receptor of 5.47  0.429. These CRIP1a/CB1 receptor molar ratios are
statically different (t-test, p < 0.001). Interestingly, mouse cerebellum has a CRIP1a/CB1
receptor molar ratio of 33.6  5.19, which indicates a molar excess of CRIP1a compared
to the CB1 receptor, similar to the hCB1-HEK cell line, although somewhat greater in
magnitude.
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Figure 10. Quantitative western blot analysis of CRIP1a concentration in hCB1-HEK
cells (CRIP1a transfection) and rat cerebellum. CRIP1a purified via GST-pulldown
methodology generated a CRIP1a concentration curve. Probed membrane preparations
(A) hCB1-HEK cells (CRIP1a transfection) (70 g/sample) and (B) mouse cerebellum
(100 g/sample) using anti-CRIP1a antisera 077.4 (Elphick, rabbit, 1:500) followed by
Licor Odyssey goat anti-rabbit 800 CW IR dye (1:5,000). Mouse cerebellum loading
control probed using anti--tubulin (Santa Cruz Biotechnology, 1:500) followed by Licor
Odyssey goat anti-mouse 680 IR dye (1:5,000). Images were analyzed via Licor Odyssey
Infrared Imaging System. Unknown CRIP1a concentrations were calculated by linear
regression analysis using Microsoft Excel. Images are from a representative immunoblot
of 3 replicates.
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CB1

CRIP1a

Molar Ratio

(pmol/mg)

(pmol/mg)

(CRIP1a/CB1)

hCB1-HEK

1.64  0.298

0.564  0.131

0.376 ± 0.875

hCB1-HEK-CRIP1a

1.51  0.308

8.20  0.643

5.47 ± 0.429*

Rat Cerebellum

3.63  0.371

115  12.2

33.6 ± 5.19

Table 3. Stoichiometric molar ratio of CRIP1a/CB1 in hCB1-HEK cells (CRIP1a
transfection) and rat cerebellum. Data are mean Bmax values from saturation analysis of
[3H]SR141716A binding  SEM for CB1 receptor expression, CRIP1a concentration
(pmol/mg) determined via immunoblot  SEM, and resulting molar ratio  SEM (n=4).
Stable CRIP1a transfection caused a significant increase in CRIP1a expression, creating a
significant molar excess relative to CB1 receptor expression ( * = p < 0.001 different from
hCB1-HEK cells lacking CRIP1a transfection).
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3.4 CRIP1a Modulation of Ligand Specific CB1 Receptor-Generated G-protein
Activation; [35S]GTPS Binding in hCB1-HEK ( CRIP1a) Lines.
The interaction of CRIP1a with the intracellular surface of CB1 receptors could
affect the ability of the receptor to activate G-proteins. Indeed, Neihaus et al. (2007)
have reported that co-expression of CRIP1a with CB1 receptors in SCG neurons decreased
the basal activity of CB1 receptors without altering WIN-stimulated activity (see
Introduction 1.6). I hypothesize that the effects of CRIP1a on CB1 receptor basal activity
downstream are generated at the level of acute G-protein activation, and that CRIP1a coexpression will decrease constitutive CB1 receptor-mediated G-protein activation, but not
in G-protein activation induced by agonist ligands. Therefore, to determine the effects of
CRIP1a on basal and agonist stimulated CB1 receptor mediated G-protein activity,
[35S]GTPS binding was performed in hCB1-HEK ( CRIP1a) cells (Figure 11). A wide
variety of CB1 ligands were tested, including the classical phytocannabinoid THC, and its
synthetic nantradol analog Levo, the aminoalkylindole WIN, the nonclassical bicyclic
CP, the eicosanoid MethA (a stable analog of the endocannabinoid anandamide), the
diarylpyrazole inverse agonist SR1, the classical synthetic cannabinoid HU210, and the
putative endogenous cannabinoid Nol Eth.
In hCB1-HEK cells, Nol Eth appeared to act as a full agonist, while WIN, CP and
HU210 also acted as high efficacy agonists. MethA and Levo acted as high to moderate
efficacy partial agonists, THC acted as a low efficacy partial agonist and SR1 acted as an
inverse agonist. Interestingly, CRIP1a co-expression reduced the apparent inverse
agonism of SR1 (Figure 16), in agreement with Neihuas et al. (2007). SR1 produced –
13.34  1.65% stimulation which was reduced to –7.33  1.21 in the presence of CRIP1a.
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Figure 11. Ligand-induced [35S]GTPS binding in hCB1-HEK and hCB1-HEK-CRIP1a
cells. The top panel shows concentration-effect curves for WIN, MethA, and Levo, the
middle panel shows curves for CP, THC and SR1, and the bottom panel shows curves for
HU210 and Nol Eth. Data points are mean % stimulation  SEM (n=3). All experiments
were performed in the presence of 100 mM NaCl.
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Figure 12. Emax values for Nol Eth, HU210, WIN, CP, MethA, THC, Levo and SR1 in
membranes from hCB1-HEK cells with and without co-expression of CRIP1a. Data are
mean Emax values derived from the concentration-effect curves shown in Figure 11 
SEM (n=3). Significant differences were found for the Emax values of Nol Eth, HU210,
WIN, CP and SR1 in cells with CRIP1a co-expression compared to those without. *,**: p <
0.05, 0.01 different from the corresponding drug in non-CRIP1a expressing cells by
ANOVA with post-hoc Newman-Keuls Test.
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CRIP1a also reduced CB1 receptor-mediated G-protein activation of the high
efficacy agonists Nol Eth, HU210, WIN and CP. Nol Eth produced an Emax value of
158.2  16.6% in hCB1-HEK cells, which was significantly reduced to an Emax value of
108.1  6.7% in hCB1-HEK-CRIP1a cells. Nol Eth produced an Emax value of 129.5 
13.9% in hCB1-HEK cells, which was significantly reduced to an Emax value of 85.6 
14.5% in hCB1-HEK-CRIP1a cells. WIN produced an Emax value of 111.10  6.66%
stimulation in hCB1-HEK cells, which was significantly reduced to an Emax value of
79.47  2.46% in hCB1-HEK-CRIP1a cells. CP stimulated hCB1-HEK cells to an Emax
value of 100.10  9.32% which CRIP1a co-expression significantly reduced to an Emax
value of 74.95 7.69%.
Stimulation by MethA, Levo, and THC were unaffected by CRIP1a (Emax value of
84.55  8.48% stimulation by MethA in hCB1-HEK cells compared to Emax value of
80.23  8.02% in hCB1-HEK-CRIP1a). Levo produced an Emax value of 73.28  4.07% in
hCB1-HEK compared to an Emax value of 72.84  4.52% in hCB1-HEK CRIP1a. THC
produced an Emax value of 17.90  2.68% in hCB1-HEK compared to an Emax value of
19.74  1.07 in hCB1-HEK CRIP1a. All data were analyzed via ANOVA (p < 0.05, n =
16, F = 84.87, R2 = 0.9725, and df = 17), with post-hoc Neuman Keuls Multiple
Comparison Test post-hoc. Significance was reached at p < 0.05.
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3.5 The Effects of CRIP1a on Spontaneous CB1 G-protein Activation; [35S]GTPS
Binding in hCB1-HEK ( CRIP1a) Cell Lines with Varying Na+ Levels.
Spontaneous CB1 receptor mediated G-protein activity in hCB1-HEK cells was
relatively small in magnitude, as determined by SR1 inhibition of [35S]GTPS binding
(see Results 3.4). Therefore, it was of interest to examine the effects of CRIP1a under
varying conditions of spontaneous CB1 receptor activity. I hypothesize that as
spontaneous CB1 receptor activity increases, the ability of CRIP1a to decrease constitutive
activity will become more pronounced. In addition, the magnitude of attenuation of the
net stimulatory effects of WIN on the CB1 receptor-mediated G-protein activity by
CRIP1a is hypothesized to decrease as a function of spontaneous receptor activity,
whereas attenuation of net SR1-inhibited G-protein activity is expected to increase as a
function of spontaneous receptor activity. Because Na+ is a negative allosteric modulator
of spontaneous GPCR activity, the effects of CRIP1a on spontaneous CB1 receptormediated G-protein activity were examined in [35S]GTPS binding studies with varying
NaCl concentrations. hCB1-HEK ( CRIP1a) cells were incubated with maximally
effective concentrations of WIN (10 M), THC (6 M), SR1 (0.05 M) or under basal
conditions and increasing doses of NaCl (0-175 mM).
For hCB1-HEK cells with and without CRIP1a co-expression, increasing sodium
concentrations lead to a decrease in overall G-protein activation for all conditions tested
(Figure 13).
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Figure 13. [35S]GTPS binding in hCB1-HEK cells (CRIP1a co-expression) with
varying NaCl concentrations. Cells were incubated with maximally effective
concentrations agonist concentrations (10 M WIN, 6 µM THC) and a maximally
inhibiting concentration of the inverse agonist SR1 (0.5 M SR1) in the presence of
varying concentrations of NaCl (0-150 mM). Data points are mean [35S]GTPS bound
(fmol/mg)  SEM (n=5). * indicates statistically significant difference in hCB1-HEKCRIP1a cells compared to identical conditions in hCB1-HEK cells via two-way ANOVA
with post-hoc Bonferroni Test (p < 0.05).
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Furthermore, CRIP1a co-expression decreased WIN-stimulated G-protein activation at all
NaCl concentrations tested, similar to the earlier experiments under 100 mM NaCl
(Figure 16). At high NaCl concentrations (> 50 mM NaCl), THC was unaffected by
CRIP1a co-expression, also as in earlier experiments (Figure 12). CRIP1a significantly
decreased GPCR- mediated G-protein activation when spontaneous CB1 activity was high
(0, 10 & 25 mM NaCl) for all conditions tested. Data were analyzed using two-way
ANOVA with Bonferroni post-hoc test, which found both a significant interaction of
CRIP1a and NaCl (p < 0.0001, DF = 7), and both CRIP1a and NaCl were a significant
source of variation for all treatment groups (p < 0.05, DF = 7).
Additionally, basal activity was subtracted from all the conditions and the data
were expressed as net fmol/mg (Figure 14). When examining net [35S]GTPS binding,
the apparent CRIP1a effects on spontaneous CB1 receptor mediated G-protein activation
at low NaCl concentrations are lost. However, the decrease in WIN-stimulated G-protein
activation in the presence of CRIP1a remains significant. Data were analyzed using twoway ANOVA with Bonferroni post-hoc test, which found a significant interaction of
CRIP1a and NaCl in WIN treated cells (p < 0.0001, DF = 56). NaCl was a significant
source of variation for all treatments (p < 0.0001). However, CRIP1a was only a
significant source of variation for WIN treatment (p = 0.0098). For each analysis, DF =
7.
Lastly, net fmol/mg data were analyzed for area under the curve (AUC) (Figure
19). CRIP1a co-expression significantly decreased AUC for WIN stimulated [35S]GTPS
binding (10000  579 fmol/mg in hCB1-HEK versus 6920  590 fmol/mg in hCB1-HEKCRIP1a cells, two-way ANOVA, p < 0.001). The presence of CRIP1a did not statistically
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affect AUC in the presence of THC (2010  143 fmol/mg in hCB1-HEK versus 1440 
189 fmol/mg in hCB1-HEK-CRIP1a cells) or SR1 (-1840  362 fmol/mg in hCB1-HEK
versus -1420  343 fmol/mg in hCB1-HEK-CRIP1a cells). However, there was a trend for
CRIP1a to decrease the apparent inverse agonism of SR1. Data were analyzed via twoway ANOVA, with post-hoc Bonferroni Test (df = 2, F = 9.910). Significance was
reached at p < 0.05.
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Figure 14. Net-stimulated [35S]GTPS binding in hCB1-HEK cells (CRIP1a coexpression) with varying NaCl concentrations. Cells were incubated with maximally
effective concentrations of cannabinoid ligands (10 M WIN, 6 µM THC) and a
maximally inhibiting concentration of the inverse agonist SR1 (0.5 M SR1) in the
presence of varying concentrations of NaCl (0-150 mM). Data are mean net-stimulated
fmol/mg  SEM (n=5). * indicates statistically significant difference in hCB1-HEKCRIP1a cells compared to identical conditions in hCB1-HEK cells via two-way ANOVA
with post-hoc Bonferroni Test (p < 0.05).
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Figure 15. Area under the curve (AUC) analysis of net-stimulated [35S]GTPS binding
studies in hCB1-HEK cells (CRIP1a co-expression) with varying NaCl concentrations.
Cells were incubated with maximally effective concentrations of cannabinoid ligands (10
M WIN, 6 µM THC) and a maximally inhibiting concentration of the inverse agonist
SR1 (0.5 M SR1) in the presence of varying concentrations of NaCl (0-150 mM) (see
figure 14). Data are mean AUC of net fmol/mg caculated from the curves shown in
Figure 14  SEM (n=5). * indicates statistically significant difference in hCB1-HEKCRIP1a cells compared to identical conditions in hCB1-HEK cells (ANOVA with posthoc Newman-Keuls Test, p < 0.05).
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3.6 [35S]GTPS in hCB1-HEK ( CRIP1a) Cell Lines with PTX Pre-treatment, with
and without 100 mM NaCl.
Given that basal and agonist G-protein activity was negatively modulated by Na+
concentrations, the previous results question whether CRIP1a modulates GPCR-mediated
G-protein activity or directly affects G-proteins. I hypothesize that CRIP1a acts
exclusively on the CB1 receptor, to which it binds, without directly interacting with Gproteins. To determine the effect of CRIP1a on GPCR-specific G-protein activation
versus non-GPCR mediated G-protein activity, [35S]GTPS binding was performed on
hCB1-HEK ( CRIP1a) cells with and without pertussis toxin (PTX) pretreatment, and in
the presence and absence of sodium (Figure 16). Under normal 100 mM Na+ conditions,
CRIP1a significantly reduced WIN stimulated [35S]GTPS binding, as seen in the
previous experiments (149.7  19.2 fmol/mg in hCB1-HEK vs. 121.5  17.1 fmol/mg in
hCB1-HEK-CRIP1a cells). In the hCB1-HEK cells lacking CRIP1a, PTX pre-treatment
significantly reduced GPCR-dependent G-protein activation. Interestingly, in CRIP1acontaining cells, there was no significant difference between cells with or without PTX
pre-treatment under basal or SR1 inhibited conditions. Data were analyzed via ANOVA
( n = 12, F = 20.28, R2 = 0.8711), with post-hoc Neuman Keuls Multiple Comparison
Test, significance reached at p <0.05.
Spontaneous G-protein activity was enhanced by the lack of Na+; under these
conditions CRIP1a decreased G-protein activation under all conditions tested.
Furthermore, in CRIP1a-containing cells, there was a significant difference between Gprotein activation with and without PTX pre-treatment for all conditions tested,
suggesting that while CRIP1a does decrease G-protein activity, it is not as effective as
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PTX when spontaneous GPCR activity is high. All data were analyzed via ANOVA (n =
12, F = 70.24, R2 = 0.9590), with post-hoc Neuman Keuls Multiple Comparison Test,
significance reached at p < 0.05.
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Figure 16. [35S]GTPS binding in hCB1-HEK cells (CRIP1a co-expression) with
varying NaCl concentrations, with and without PTX pre-treatment. NC indicates no
CRIP1a. Cells were incubated with maximally effective concentrations agonist
concentrations (10 M WIN, 6 µM THC) and a maximally inhibiting concentration of the
inverse agonist SR1 (0.5 M SR1) in the presence (top) or absence (bottom) of NaCl and
with or without PTX pre-treatment. Data points are averaged from at least independent
three experiments containing measurements made in triplicate  SEM. * indicates
statistically significant difference in hCB1-HEK-CRIP1a cells compared to identical
conditions in hCB1-HEK cells, # indicates statistically significant difference between no
treatment versus PTX pre-treatment within the cell type (ANOVA with post-hoc
Newman-Keuls Test, p < 0.05).
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3.7 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry
(LC-ESI-MS-MS) Analysis of Endocannabinoids in hCB1-HEK ( CRIP1a) Cell
Lines.
Basal G-protein activity in CB1 receptor expressing cells can be due in part to the
presence of endocannabinoids or to actual spontaneous GPCR-mediated G-protein
activity. To determine whether endocannabinoids were present in sufficient levels to
activate CB1 receptors, the levels of the two established endocannabinoids, AEA and 2AG, were measured via liquid chromatography electrospray ionization tandem mass
spectrometry (LC-ESI-MS-MS) in hCB1-HEK ( CRIP1a) cell lines (Table 4). For both
cells types, 3 samples of whole cells (10 x 106 cells) or membrane preparations (1,000
g) were analyzed. There were no detectable levels of AEA or 2-AG in whole cell or
membrane preparations for either hCB1-HEK ( CRIP1a) cell lines.
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hCB1-HEK
6

AEA (pmol)

2-AG (nmol)

None Detected

None Detected

None Detected

None Detected

None Detected

None Detected

None Detected

None Detected

Whole cells (10 x 10 )
hCB1-HEK
Membrane prep (1,000 g)
hCB1-HEK-CRIP1a
6

Whole cells (10 x 10 )
hCB1-HEK-CRIP1a
Membrane prep (1,000 g)

Table 4. Endocannabinoid levels in CB1 in hCB1-HEK cells (CRIP1a co-expression).
Liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MSMS) was used to determine the levels of two endocannabinoids, AEA and 2-AG in whole
cell and membrane preparations of hCB1-HEK cells (CRIP1a co-expression). Data are
mean values (pmol/nmol)  SEM of three independent experiments. No AEA or 2-AG
were detected in either cell line or either preparation type.
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3.8 CRIP1a Effects on CB1 Receptor Desensitization; [35S]GTPS Binding in Drugtreated hCB1-HEK ( CRIP1a) Cell Lines.
The CB1 receptor C-terminus is important in the regulation of CB1 receptor
signaling by the GRK/-arrestin pathway, as described in Introduction 1.4. CRIP1a is
known to interact with the CB1 receptor C-terminus and therefore could modulate the
response of this receptor to prolonged agonist occupancy, such as desensitization or
downregulation. I hypothesize that CRIP1a will affect CB1 receptor desensitization;
CRIP1a may only affect high efficacy ligand desensitization induced by WIN treatment as
a result of reduced CB1 receptor-mediated G-protein activation, or could affect the
desensitization induced by all full and partial agonist ligands as a result of steric
hindrance with receptor regulatory proteins such as GRK or β-arrestin. To determine the
effects of CRIP1a on CB1 receptor desensitization, hCB1-HEK ( CRIP1a) cells were preincubated with WIN (10 M), THC (6 M) or vehicle for 4 hours, followed by MethAstimulated [35S]GTPS binding to assess CB1 receptor function (Figure 17). MethA was
used to assess CB1 activation because acute stimulation of [35S]GTPS binding by this
ligand was unaffected by CRIP1a (Figure 12).
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Figure 17. [35S]GTPS binding in hCB1-HEK cells (CRIP1a co-expression) following
four hour drug pretreatment. Cells were pre-treated with maximally effective
concentrations of agonist (10 M WIN, 5 µM THC) or vehicle and subjected to MethAstimulated [35S]GTPS binding. Concentration effect curves were generated for vehicle,
WIN and THC-treated cells. Data points are mean % stimulation  SEM (n=4).
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Two-way ANOVA of Emax values indicate that drug pretreatment was a
significant source of variation (df = 2, F = 73.69, significance reached at p < 0.05),
suggesting that pretreatment with either WIN or THC caused significant desensitization
of the CB1 receptor. However, there was no significant effect of CRIP1a or an interaction
between CRIP1a and drug treatment. Similarly, as reveled by two-way ANOVA, EC50
values were affected by drug treatment (df = 2, F = 7.418 significance reached at p <
0.05), but there was no effect of CRIP1a nor an interaction between the two. Therefore,
CRIP1a did not affect cannabinoid-induced CB1 receptor desensitization.
Subsequent 1-way ANOVA with Newman-Keuls Multiple Comparison Test
(significance reached at p < 0.05, n = 6) revealed that both Emax and EC50 values for WIN
and THC pre-treatment were significantly different from vehicle (Table 5), except for the
Emax value of THC pre-treated hCB1-HEK-CRIP1a cells. ANOVA of Emax yielded F =
30.11 and R2 = 0.8931, and ANOVA of EC50 yielded F = 6.442 and R2 = 06823.
Pretreatment with WIN decreased the Emax value of MethA by 66.5 % in hCB1-HEK
cells and by 67.0 % in hCB1-HEK-CRIP1a cells compared to vehicle. Pretreatment with
THC decreased the Emax value of MethA by 21.9 % in hCB1-HEK cells and by 7.2 % in
hCB1-HEK-CRIP1a cells compared to vehicle. Pretreatment with WIN or THC resulted
in an approximately 10-fold increase in EC50 values.

The basal values of G-protein activation were unchanged by CRIP1a for all
treatment groups (48.9  1.92 fmol/mg, 47.3  2.71 fmol/mg and 55.6  1.83 fmol/mg in
hCB1-HEK cells for vehicle, WIN and THC treatment, respectively, and 43.9  4.21
fmol/mg, 55.0  10.5 fmol/mg and 45.5  1.98 fmol/mg in hCB1-HEK-CRIP1a cells for

73
vehicle, WIN and THC treatment, respectively). Data were analyzed via ANOVA, with
post-hoc Neuman Keuls Multiple Comparison Test. Significance was reached at p <
0.05.
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hCB1-HEK

Emax (% Stimulation)

EC50 (μM)

128  8.04

0.308  0.071

43.1  7.07 *

5.70  2.11 *

100  8.55 *

3.00  0.049 *

112  5.10

0.423  0.082

37.0  4.73 *

4.16  0.595*

104  7.37

5.17  1.31*

Vehicle Treated
hCB1-HEK
WIN Treated
hCB1-HEK
THC Treated
hCB1-HEK-CRIP1a
Vehicle Treated
hCB1-HEK-CRIP1a
WIN Treated
hCB1-HEK-CRIP1a
THC Treated

Table 5. Emax and EC50 values from concentration-effect curves of MethA-stimulated
[35S]GTPγS binding in hCB1-HEK cells (CRIP1a) following four hour pre-treatment
with vehicle, WIN or THC. Data are means values derived from the concentration-effect
curves shown in Figure 21 ± SEM (n=4). * indicates statistically significant difference
from vehicle treatment within cell type via one-way ANOVA with post-hoc NewmanKeuls Multiple Comparison Test (p < 0.05).

75

3.9 CRIP1a Effects on CB1 Receptor Downregulation; [3H]SR141716A Saturation
Analysis in Drug-treated hCB1-HEK ( CRIP1a) Cell Lines.
Although CRIP1a did not have a significant effect on CB1 receptor desensitization,
the CRIP1a binding site on the CB1 receptor is known to be near the binding site for
GASP1, a protein involved in CB1 receptor downregulation (see Introduction 1.4).
Therefore, I hypothesize that CRIP1a may be able to affect CB1 receptor downregulation
without affecting desensitization. To determine the effects of CRIP1a on CB1 receptor
downregulation, hCB1-HEK ( CRIP1a) cells were pre-incubated with WIN (10 M),
THC (6 M) or vehicle for 4 hours, followed by [3H]SR141716A saturation analysis to
assess CB1 receptor expression (Figure 18).
In hCB1-HEK cells, both WIN and THC caused significant downregulation of the
CB1 receptor. WIN pretreatment decreased the [3H]SR141716A Bmax value to 48.2 
7.9% of vehicle control and pretreatment with THC decreased the Bmax value to 23.6 
7.8% of vehicle control for hCB1-HEK cells. Absolute Bmax values for vehicle, WIN and
THC treated hCB1-HEK cells were 1.09  0.06 pmol/mg, 0.53  0.08 pmol/mg, and 0.26
 0.08 pmol/mg, respectively.
CRIP1a attenuated WIN-induced CB1 receptor downregulation. WIN pretreatment
decreased the Bmax value to 85.9  22.1% of vehicle control in hCB1-HEK-CRIP1a cells,
which was not significantly different from control. However, CRIP1a did not
significantly decrease THC-induced downregulation. The Bmax value (50.4  25.6% of
vehicle control) in THC-treated hCB1-HEK-CRIP1a cells was not significantly different
from the Bmax value of THC-treated hCB1-HEK cells (23.6  7.8%). Absolute Bmax
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values for vehicle, WIN and THC treated hCB1-HEK-CRIP1a cells were 1.28  0.22
pmol/mg, 0.99  0.22 pmol/mg, and 0.49  0.21 pmol/mg, respectively. Data were
analyzed via one-way ANOVA (n= 6, F = 7.493, R2 = 0.6408) with post-hoc Neuman
Keuls Multiple Comparison Test. Significance was reached at p < 0.05.
Further analysis examined absolute Bmax and Kd values (Table 6). In agreement
with % vehicle data, WIN and THC caused significant downregulation of the CB1
receptor in hCB1-HEK cells, which CRIP1a co-expression prevented in WIN pre-treated
cells. Furthermore, the KD values were not significantly different between vehicle and
drug pretreated groups in either cell line, indicating effective removal of the drug
following pretreatment.
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Figure 18. CB1 receptor levels in hCB1-HEK cells (CRIP1a co-expression) following
four hour drug pretreatment. Cells were pre-treated with maximally effective
concentrations agonist concentrations (10 M WIN, 5 µM THC) or vehicle. Bmax
(pmol/mg) values were obtained by [3H]SR141716A saturation analysis and are
expressed as mean % of vehicle control  SEM (n=4). * indicates statistically significant
difference from vehicle within each cell type, # indicates statistically significant
difference comparing two cell types with the same treatment (ANOVA with post-hoc
Newman-Keuls Test, p < 0.05).
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hCB1-HEK

Bmax (pmol/mg)

KD (nM)

1.09  0.065

1.48  0.346

0.531  0.089*

0.984  0.272

0.260  0.087*

1.12  0.997

1.28  0.227

2.93  0.675

0.994  0.220

3.11  1.16

0.499  0.214*

2.42  1.24

Vehicle Treated
hCB1-HEK
WIN Treated
hCB1-HEK
THC Treated
hCB1-HEK-CRIP1a
Vehicle Treated
hCB1-HEK-CRIP1a
WIN Treated
hCB1-HEK-CRIP1a
THC Treated

Table 6. Bmax and KD values from [3H]SR141716A binding studies using hCB1-HEK
cells (CRIP1a) following four hour pre-treatment with vehicle, 5 µM WIN or 10 µM
THC. Data are mean values ± SEM (n=4). * indicates statistically significant difference
from vehicle treatment within cell type via one-way ANOVA (p < 0.05) with post-hoc
Neuman Keuls Multiple Comparison Test.
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3.10 Effect of CRIP1a on CB1 receptor mediated modulation of cAMP generation in
hCB1-HEK ( CRIP1a) cell lines.
CRIP1a acutely decreased spontaneous G-protein activation and the G-protein
activation induced by certain cannabinoid ligands. Therefore, it is of interest to
determine if the acute modulation of CB1 receptor mediated G-protein activity translates
into effects on CB1 receptor mediated downstream signaling events. I hypothesize that
CRIP1a will attenuate the constitutive inhibition of cAMP, but not agonist-mediated
effects on cAMP, by the CB1 receptor, in agreement with results found by Neihaus et al.
on the voltage-gated Ca+2 channels.
Modulation of 10µM forskolin-stimulated cAMP generation in hCB1-HEK (
CRIP1a) cell lines was examined in intact cells incubated with maximally effective
concentrations of 2 M WIN, 3 M THC, 0.2 M SR1 or vehicle (Figure 19). In hCB1HEK cells, CB1 activation by the full agonist WIN caused a significant decrease in cAMP
levels (32.7  2.96 pM cAMP in vehicle vs. 12.7  2.88 pM cAMP for WIN treatment).
THC also appeared to cause a decrease in cAMP, but it was not significantly different
from vehicle (20.1  1.06 pM). The inverse agonist SR1 nearly doubled cAMP levels
compared to control (62.0  1.9 pM). The presence of CRIP1a did not significantly alter
cAMP levels in the presence of vehicle alone (21.9  3.34 pM), nor the significant
decrease in cAMP levels due to the full agonist WIN (12.7  2.77 pM, p < 0.05 different
from vehicle condition) or cAMP levels observed with THC treatment (23.4  1.7 pM).
Notably, CRIP1a co-expression abolished the inverse agonism of SR1, such that the levels
of cAMP in the presence of SR1 were not significantly different from vehicle-treatment
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in hCB1-HEK-CRIP1a cells (27.5  5.7 pM cAMP following SR1 treatment versus 21.9 
3.34 pM in vehicle treated cells). Moreover, the levels of cAMP in the presence of SR1
in hCB1-HEK-CRIP1a cells were significantly lower than in hCB1-HEK cells without
CRIP1a co-expression. Results were analyzed via one-way ANOVA, with significance
reached at p < 0.05 (n = 8, F = 17.51, R2 = 0.8845).
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Figure 19. Forskolin-stimulated cAMP generation in hCB1-HEK cells (CRIP1a coexpression). Cells were incubated with either 2 µM WIN, 3 µM THC, 0.2 µM SR1 or
vehicle in the presence of 10 µM forskolin and phosphodiesterase inhibitors for 8 min.
cAMP concentrations were determined using a [3H]cAMP kit [Liquid phase Cyclic AMP
(PIKAPH-2). Data are mean cAMP levels (pmol/tube)  SEM (n=4). * indicates
statistically significant difference from vehicle within each cell type, # indicates
statistically significant difference comparing two cell types with the same treatment
(ANOVA with post-hoc Newman-Keuls Test, p < 0.05).
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3.11 Immunoblot Analysis of CB1 Receptor-mediated ERK Phosphorylation in
hCB1-HEK ( CRIP1a) Cell Lines.
The modulation of intracellular kinases downstream of CB1 receptor-mediated
generation of free G is another effector cascade that plays a role in CB1 receptor
signaling. I hypothesize that CRIP1a will attenuate the constitutive CB1 receptormediated phosphorylation of ERK 1/2, similarly to cAMP inhibition (Figure 19).
The effect of CRIP1a on the ability of the CB1 receptor to modulate p42/p44 MAP kinase
(ERK 1/2) phosphorylation was examined using immunoblot techniques. hCB1-HEK (
CRIP1a) cells were serum starved for 6 hours, followed by an 8 min drug treatment with
either 2 M WIN, 3 M THC, 0.2 M SR1 or vehicle. Cells were lysed with cell lysis
buffer containing protease and phosphatase inhibitors and samples were immunoblotted
and probed for ERK and p-ERK (Figure 20). WIN, and to a lesser extent, THC,
stimulated phosphorylation of ERK1 and ERK2 (Figure 21). In hCB1-HEK cells, WIN
increased ERK 1 phosphorylation to 148.64  15.61% vehicle control, and THC
increased ERK 1 phosphorylation by 117.61  10.61% vehicle control. No differences
were seen in results between hCB1-HEK for hCB1-HEK-CRIP1a cells, as WIN and THC
stimulated ERK1 phosphorylation by 140.15  1.85% vehicle control and 133.71 
10.25% vehicle control in hCB1-HEK-CRIP1a cells, respectively.
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Figure 20. Western blot of p44/p42 ERK phosphorylation in hCB1-HEK cells (CRIP1a
transfection). Membrane preparations of hCB1-HEK cells (CRIP1a transfection) (50 g)
were probed using phosphorylated ERK 1/2 antibody (1:200 Santa Cruz) and ERK 1
antibody for loading control (1:250, Chemicon). Images are from one representative
experiment of 3 replicates, and were generated using Licor Odyssey software.
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SR1 inhibited ERK1 phosphorylation in hCB1-HEK cells, decreasing
phosphorylation to 69.48  25.92% vehicle control. In hCB1-HEK-CRIP1a cells, SR1
inhibited ERK1 phosphorylation did not appear to decrease from vehicle (90.05 
14.01% vehicle control), however, there was no statistically significant differences
between p-ERK levels obtained in hCB1-HEK with and without CRIP1a co-expression.
CB1 receptor mediated phosphorylation of ERK2 followed a similar pattern to
ERK1. WIN and to a lesser extent, THC, stimulated ERK 2 phosphorylation (147.44 
10.66% vehicle control and 124.34  7.78% vehicle control for WIN and THC,
respectively) in hCB1-HEK cells, with no significant differences in results seen between
hCB1-HEK and hCB1-HEK-CRIP1a cells (145.18  10.36% vehicle control and 140.38 
5.11% vehicle control for WIN and THC, respectively, in HEK-CRIP1a cells). Once
again, SR1 appeared to decrease ERK2 phosphorylation to a greater exent in hCB1-HEK
compared to hCB1-HEK-CRIP1a cells, (84.37  14.77% vehicle control in hCB1-HEK vs.
95.56 10.89% vehicle control), however, there were no significant differences in hCB1HEK cells with and without CRIP1a co-expression.
Lysates were also immunoblotted for non-phosphorylated ERK1 and ERK2
levels, to serve as loading controls. No significant differences were for observed for
ERK1 or ERK2 levels in the presence or absence of any CB1 receptor ligand.
All data were analyzed via ANOVA, significance achieved at p < 0.05, followed
by a post-hoc Newman-Keuls Multiple Comparison Test (n = 8, F = 4.468, R2 = 0.6615).
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Figure 21. Densitometric analysis of p44/p42 ERK 1/2 immunoblot. The upper two
panels show the effect of 2 µM WIN, 3 µM THC, or 0.2 µM SR1 on phosphorylation
levels of p-44 ERK 1 (p-ERK 1, left) and p-42 ERK 2 (p-ERK 2, right). The lower two
panels display the loading control values of p44 ERK 1 (ERK1) and p42 ERK 2 (ERK2).
All data are mean values  SEM expressed as normalized to vehicle alone (100%) (n=3).
All values were derived from integrated intensity values obtained using Licor Odyssey
software. No statistically significant differences between the two cell types were
observed (ANOVA with post-hoc Newman-Keuls Test, p < 0.05).
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3.12 CRIP1a Immunoblot Analysis of Hippocampi from THC Treated Mice.
Results in the HEK cell model indicate that CRIP1a co-expression could alter the
adaptation of CB1 receptors to prolonged agonist treatment in that CRIP1a inhibited WINmediated CB1 receptor downregulation. It was of interest to determine whether
prolonged administration of cannabinoid agonists could modulate CRIP1a expression. I
hypothesize that CRIP1a levels will be altered in response to THC exposure, similarly to
other CB1 receptor interacting proteins involved in receptor regulation, such as the GRKs
and β-arrestins (Rubino et al. 2006). CRIP1a expression in the HEK cells was driven by a
viral promoter, and thus changes in CRIP1a expression may not be physiological relevant
to mammalian models. To determine if cannabinoid exposure alters CRIP1a expression in
vivo, an animal model was used. Hippocampus was chosen for examination, as CRIP1a
expression in this region is very dense according to immunohistochemical staining of
rodent brain by Dr. Maurice Elphick (unpublished data).
To determine whether chronic THC administration in the mice alters CRIP 1a
expression in the hippocampus, mice were treated with chronic, ramping doses (10, 20,
30 mg/kg, 2 injections per day for 6.5 days) of THC or vehicle. Hippocampi were
harvested and subjected to immunoblot analysis for CRIP1a expression (Figure 22).
Prolonged THC administration did not alter CRIP1a expression in mouse hippocampi.
Integrated intensity of CRIP1a bands generated by the Licor Odyssey system were 24.73
 1.31 for THC treated mice and 26.64  0.80 for vehicle treated mice, which were not
significantly different according to a two-tailed t-test (p > 0.05, t = 1.240, df = 6). In
addition, mouse hippocampi were immunoblotted for the presences of -tubulin as a
loading control. There were no significant differences in -tubulin levels (integrated
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intensity of 48.50  2.29 for THC treated mice and 55.01  2.43 for vehicle treated mice),
according to a two-tailed t-test (p > 0.05, t = 1.944, df = 6).
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Figure 22. CRIP1a immunoblot analysis of hippocampi from THC treated male ICR
mice. Mice were treated with chronic, ramping doses of THC or vehicle. A)
Hippocampi were harvested and membrane preparations (100 g protein) were probed
using anti-CRIP1a antisera 077.4 (Elphick, rabbit, 1:500) followed by Licor Odyssey goat
anti-rabbit 800 CW IR dye (1:5,000). Loading control was probed using anti--tubulin
(Santa Cruz Biotechnology, 1:500) followed by Licor Odyssey goat anti-mouse 680 IR
dye (1:5,000). Images were analyzed via Licor Odyssey Infrared Imaging System. B)
Data are mean densitometric values  SEM (n = 4 animals for each treatment group, and
the immunoblot was replicated twice with similar results). There were no significant
differences in levels of CRIP1a or -tubulin loading control between mice treated with
THC or vehicle (students t test, p < 0.05).
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3.13 CB1 Receptor Expression in mCB1-CHO and mCB1-CHO-CRIP1a Cell Lines.
Due to the modulatory effects of CRIP1a co-expression on CB1 receptor signaling
and adaptation in the HEK cell model, it was of interest to determine whether CRIP1a coexpression would have similar effects on CB1 receptor function in a different cell line.
To address this question, CHO cells stably transfected with the CB1 receptor were stably
co-transfected with CRIP1a. Cells expressing high levels of CRIP1a were chosen for
further study. I hypothesize that CRIP1a will not affect CB1 receptor expression, as seen
in the HEK cell model.
CB1 receptor expression in mCB1-CHO and mCB1-CHO-CRIP1a cell lines were
quantified using [3H]SR141716A saturation analysis. Stable transfection of CRIP1a did
not affect CB1 receptor number (Table 7) (Bmax value of 7.71  1.63 pmol/mg in mCB1CHO cells versus Bmax value of 5.48  0.72 pmol/mg in mCB1-CHO-CRIP1a cells).
Furthermore, no significant differences were seen in [3H]SR141716A KD values (2.08 
0.16 nM in mCB1-CHO cells versus 1.23  0.39 nM in mCB1-CHO-CRIP1a cells). Data
were analyzed using two-tailed t-test with significance reached at p < 0.05 (n = 4, df = 3,
t = 1.537).
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Bmax

KD

(pmol/mg)

(nM)

mCB1-CHO

7.72 ± 1.63

2.08 ± 0.16

mCB1-CHO-CRIP1a

5.48 ± 1.23

1.23 ± 0.39

Table 7. Bmax and KD values from saturation analysis of [3H]SR141716A binding in
mCB1-CHO cells with and without CRIP1a co-expression. Bmax values represent total cell
membrane receptor levels. Data are mean values ± SEM (n=4). No significant
differences between the two CHO cell types were observed (two-tailed t-test, p > 0.05).
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3.14 Stoichiometric Relationship of CRIP1a to CB1 Receptor in mCB1-CHO and
mCB1-CHO-CRIP1a Cell Lines.
To determine the stoichiometric relationship of CRIP1a to CB1 receptor in mCB1CHO and mCB1-CHO-CRIP1a cell lines, immunoblot analysis of CRIP1a was performed
using a GST-pulldown purified CRIP1a concentration curve for comparison to cell line
samples and analyzed on the Licor Odyssey system (Figure 23). I hypothesize, that like
HEK cells, CRIP1a transfection will increase the stoichiometric relationship of CRIP1a to
CB1 receptor. CRIP1a concentrations were inferred from a linear regression of the
concentration curve in Micrsoft Excel, and the unknown CRIP1a concentrations of mCB1CHO and mCB1-CHO-CRIP1a membrane preparations were determined (Table 8).
mCB1-CHO-CRIP1a cells express significantly more CRIP1a than mCB1-CHO cells (7720
 1370 pmol/mg in mCB1-CHO-CRIP1a cells versus 63.1  18.0 pmol/mg in mCB1-CHO
cells) according to two-tailed t-test (p = 0.0021, df = 8, t = 4.461).
CB1 receptor levels and CRIP1a concentrations were used to generate
stoichiometric ratios for mCB1-CHO and mCB1-CHO-CRIP1a cell lines (Table 8). The
molar ratio of CRIP1a/CB1 receptor was significantly higher in mCB1-CHO-CRIP1a cells
(1930  343 pmol/mg) than in mCB1-CHO-CRIP1a cells (15.7  4.52) as analyzed by
two-tailed t-test (p = 0.0021, df = 8, t = 4.461).
Comparison of the molar ratio of CRIP1a/CB1 receptors in rat cerebellum (33.6 ±
5.19) and mCB1-CHO cells (± CRIP1a transfection), revealed that the molar ratio of
CRIP1a/CB1 receptors found in mCB1-CHO cells without CRIP1a transfection (15.7 
4.52) was closer to that found in rat cerebellum than the ratio found in the mCB1-CHOCRIP1a cell line (1930  343 pmol/mg). Additionally the molar ratio of CRIP1a/CB1
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receptors in mCB1-CHO cells was greater than the molar ratio of CRIP1a/CB1 receptors
found in either hCB1-HEK or hCB1-HEK-CRIP1a cell lines (ANOVA with NewmanKeuls Multiple Comparisons post-hoc test, p < 0.05).
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Figure 23. Quantitative western blot analysis of CRIP1a concentration in mCB1-CHO
cells (CRIP1a transfection). CRIP1a purified via GST-pulldown methodology generated
a CRIP1a concentration curve. Membrane preparations of mCB1-CHO cells (CRIP1a
transfection) (70 g/sample) were probed using anti-CRIP1a antisera 077.4 (Elphick,
rabbit, 1:500) followed by Licor Odyssey goat anti-rabbit 800 CW IR dye (1:5,000).
Images were analyzed via Licor Odyssey Infrared Imaging System. Unknown CRIP1a
concentrations were calculated using linear regression on Microsoft Excel. Image is
representative of immunoblot of 3 replicates.
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mCB1-CHO

mCB1-CHO-

CB1

CRIP1a

Molar Ratio

(pmol/mg)

(pmol/mg)

(CRIP1a/CB1)

7.72 ± 1.63

63.1 ± 18.0

15.7 ± 4.52

5.48 ± 1.23

7720 ± 1370*

1930 ± 343*

CRIP1a

Table 8. Stoichiometric molar ratio of CRIP1a/CB1 receptor in mCB1-CHO cells
(CRIP1a transfection). Data are mean values  SEM (n=4). Bmax values represent total
cell membrane CB1 receptor levels. Stable CRIP1a transfection caused a significant
increase in CRIP1a expression, creating a significant molar excess relative to CB1 receptor
expression (* = p < 0.05 different from mCB1-CHO cells lacking CRIP1a transfection in
two-tailed t-test).
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3.15 CRIP1a Modulation of Ligand-Specific CB1 Receptor-Mediated G-protein
Activation; [35S]GTPS Binding Studies in mCB1-CHO ( CRIP1a) Cell Lines.
To determine the effects of CRIP1a over-expression on CB1 receptor mediated Gprotein activation by specific cannabinoid ligands, [35S]GTPS binding assays were
performed in mCB1-CHO ( CRIP1a) cell lines with WIN, THC and SR1 (Figure 24). I
hypothesize that greater CRIP1a expression will decrease the constitutive and high
efficacy ligand activation of CB1 receptor-mediated G-protein activity, similarly to the
HEK cell model.
Unlike results in hCB1-HEK-CRIP1a cell line, the CRIP1a significantly increased
WIN stimulated Emax values (228.0  26.58% in mCB1-CHO-CRIP1a cells versus 122.61
 36.50% in mCB1-CHO cells) according to two-tailed t-test (p < 0.05, n = 5, df = 4, t =
3.731) (Figure 29). Over-expression of CRIP1a also significantly increased the percent
stimulation by a single, maximally effective concentration (6 M) of THC (125.7 
11.4% in mCB1-CHO-CRIP1a cells vs. 83.6  19.9% in mCB1-CHO cells) according to
two-tailed t-test analysis (p < 0.05, n = 4, df = 3, t = 4.033).
Notably, CRIP1a significantly decreased the inverse agonism of SR1 (Emax value
of 27.33  7.18% in mCB1-CHO-CRIP1a cells versus 39.10  4.31% in mCB1-CHO cells,
as indicated by two-tailed t-test (p < 0.05, n = 4, df = 3, t = 5.644). This finding is in
agreement with results seen in hCB1-HEK cells with and without CRIP1a co-expression.
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Figure 24. [35S]GTPS binding in mCB1-CHO and mCB1-CHO-CRIP1a cells.
Concentration effect curves were generated for WIN and SR1. Data points are mean %
stimulation  SEM (n=4). All experiments performed in the presence of 100 mM NaCl.
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Figure 25. Emax values for WIN and SR1 and percent stimulation for THC in membranes
from mCB1-CHO cells with and without over-expression of CRIP1a. Data are mean
values  SEM (n=4). A) CRIP1a expression significantly increased the Emax value of
WIN and decreased the negative Emax value of the inverse agonist SR1. B) CRIP1a
significantly increased the % stimulation by 6 µM THC. * p < 0.05 different from the
corresponding drug in non-CRIP1a expressing cells by two-tailed t-test. # p < 0.01
different from the corresponding drug in non-CRIP1a expressing cells by two tailed t-test.
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3.16 The Effects of CRIP1a on Spontaneous CB1 G-protein Activation; [35S]GTPS
in mCB1-CHO ( CRIP1a) Cell Lines with Varying Na+ Levels.
To examine the effects of CRIP1a on spontaneous CB1 G-protein activation,
mCB1-CHO cells were incubated with maximally effective concentrations of WIN (10
M), THC (6 M), SR1 (0.05 M) or under basal conditions as well as incubated with
increasing concentrations of NaCl (0-175 mM) (Figure 26). Decreasing NaCl
concentrations lead to greater overall G-protein activity for all treatment conditions.
However, CRIP1a had no effect on G-protein activation at the various NaCl
concentrations in the presence or absence of WIN, THC or SR1 as analyzed by two-way
ANOVA, significance reached at p < 0.05.
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Figure 26. [35S]GTPS binding in mCB1-CHO cells (CRIP1a over-expression) with
varying NaCl concentrations. Cells were incubated with maximally effective
concentrations agonist concentrations (10 M WIN, 6 µM THC) and a maximally
inhibiting concentration of the inverse agonist SR1 (0.5 M SR1) in the presence of
varying concentrations of NaCl (0-150 mM). Data points are mean [35S]GTPS bound
(fmol/mg)  SEM (n=6). No statistical differences were found between the two cell
types (ANOVA with post-hoc Newman-Keuls Test (p < 0.05).
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3.17 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry
(LC-ESI-MS-MS) Analysis of Endocannabinoids in mCB1-CHO ( CRIP1a) Cell
Lines.
LC-ESI-MS-MS was utilized to measure the endocannabinoid levels of of AEA
or 2-AG. I hypothesize that CRIP1a will not affect endocannabinoid levels, as in the HEK
cell model. For mCB1-CHO cells with and without CRIP1a over-expression, 3 samples of
whole cells (10 x 106 cells) or membrane preparations (1,000 g) were analyzed (Table
9). No detectable levels of AEA were found in whole cell or membrane preparations of
mCB1-CHO ( CRIP1a) cell lines. No detectable levels of 2-AG were found in the
membrane preparations of mCB1-CHO ( CRIP1a) cell lines. However, 2-AG was
detected in whole cell extracts of mCB1-CHO cells (0.074  0.0020 nmol), which was
significantly increased by the over-expression of CRIP1a (0.22  0.020 nmol) (two-tailed
t-test, p = 0.0023, df = 4, t = 6.949).
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mCB1-CHO
Whole cells (10 x 106)

AEA (pmol)

2-AG (nmol)

None Detected

0.074 ± 0.0020

None Detected

None Detected

None Detected

0.22 ± 0.020*

None Detected

None Detected

mCB1-CHO
Membrane prep (1,000 g)
mCB1-CHO -CRIP1a
6

Whole cells (10 x 10 )
mCB1-CHO -CRIP1a
Membrane prep (1,000 g)

Table 9. Endocannabinoid levels in mCB1-CHO cells (CRIP1a over-expression).
Liquid chromatography electrospray ionization tandem mass spectrometry determined the
levels of two endocannabinoids, AEA and 2-AG, in whole cell and membrane
preparations of mCB1-CHO cells (CRIP1a over-expression). Data are mean values
(nmols)  SEM (n=3). No AEA was detected in either cell line or either preparation type.
CRIP1a over-expression significantly up-regulated 2-AG levels in whole cell preparations
of mCB1-CHO cells (students t-test, p = 0.0023), however no 2-AG was detected in
membrane preparations of either cell type.
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Chapter 4. Conclusions.

4.1 CB1 Receptor Expression; Effect of CRIP1a Transfection and Cell Confluency
CB1 receptor expression was not affected by CRIP1a co-transfection when
comparing hCB1-HEK and hCB1-HEK-CRIP1a cell lines at 100% confluency (Table 2),
in agreement with Neihaus et al., and the proposed hypothesis that CRIP1a does not affect
total expression levels of the CB1 receptor. This lack of effect of CRIP1a on CB1 receptor
expression at high confluency is particularly convenient for studies comparing effects on
CB1 receptor function in HEK cells, as alterations in CB1 receptor signaling can be
directly attributed to CRIP1a and not to alterations in CB1 receptor levels.
Furthermore, KD values were unaffected by the presence of CRIP1a, indicating
that CRIP1a did not alter the binding of [3H]SR141716A to the CB1 receptor. Therefore,
CRIP1a effects on inverse agonist properties of SR1 are unlikely to be due to changes in
affinity of the CB1 receptor for SR1.
Low cell confluency decreased CB1 receptor expression in hCB1-HEK cells, but
not hCB1-HEK-CRIP1a cells (Figure 9). Cell confluency affects protein expression in
cultured cells (Wolthuis et al. 1993). Low CB1 receptor expression in low confluency
hCB1-HEK cells may be due to the greater growth rate of low confluency cells. During
rapid cell proliferation, expression of transfected proteins may be suppressed, as
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proposed in the hypothesis that CB1 receptor expression would be negatively influenced
by cell confluency. However, this effect was not seen in cells co-transfected with
CRIP1a, suggesting that CRIP1a co-expression may stabilize the expression of the CB1
receptor in rapidly dividing cells. CB1 receptor levels were not affected by cell
confluences above 95% in either cell line. Therefore, cells were harvested for use at 95%
confluency or above for all further experiments.
4.2 Stoichiometric Relationship of CRIP1a/CB1 Receptor in hCB1-HEK ( CRIP1a)
Cell Lines and Mouse Cerebellum.
The stoichiometric molar ratio of CRIP1a/CB1 receptor in hCB1-HEK cells was
less than one (0.376), compared to hCB1-HEK-CRIP1a cells in which the ratio was greater
than one (5.47), and was increased by CRIP1a transfection as hypothesized (Table 3).
This allowed for the comparison of a cell line in which the CB1 receptor is in excess over
CRIP1a in hCB1-HEK cells compared to a cell line in which CRIP1a is in excess to the
CB1 receptor in hCB1-HEK-CRIP1a cells. The physiological relevance of the CRIP1a/CB1
receptor ratio in hCB-HEK-CRIP1a cells was verified in mouse cerebellum, where the
native stoichiometric molar ratio of CRIP1a/CB1 receptor was significantly greater than
one (33.6), indicating that under physiological conditions, CRIP1a exerts its biological
effect when there are more than sufficient CRIP1a molecules per CB1 receptor.
Cerebellum was chosen for this comparison because dense, uniform CB1 receptor
expression in the molecular layer of the cerebellar cortex (Herkenham et al. 1991; Tsou et
al. 1998), closely resembles a similar dense uniform immunoreactivity of CRIP1a in the
cerebellar cortex (Elphick et. al, unpublished data), compared to other brain regions.
Furthermore, the molecular layer of the cerebellum contains one of the densest CB1
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receptor expressions in the brain, suggesting a uniform distribution of these receptors,
making the cerebellum an appropriate location for stoichiometric comparison
(Herkenham et al. 1991). However, whole cerebellum was used for experiments, due to
the difficulty of anatomical dissection of the molecular layer. Even if only one-third of
the CRIP1a expressed in the cerebellum was co-localized in the same cells as the CB1
receptor, the CRIP1a/CB1 ratio would be no less than in the stably co-transfected HEK
cell model used the present studies. Therefore, it seems likely that hCB1-HEK-CRIP1a
cells express CRIP1a in a molar excess relative to the CB1 receptor that is no greater than
that found in native rat cerebellum. When compared to hCB1-HEK cells which lack
sufficient CRIP1a to interact with each CB1 receptor molecule, the hCB1-HEK-CRIP1a
cell line can serve as a reasonable model system to assess the effects of CRIP1a on CB1
receptor function.
4.3 CRIP1a Modulation of Acute CB1 Receptor Mediated G-protein Activation in
HEK Cells.
CRIP1a decreased acute CB1 receptor-mediated G-protein activation by the high
efficacy agonists Nol Eth, HU210, WIN and CP, while leaving acute receptor-mediated
G-protein activation by MethA, Levo, and THC unaffected in [35S]GTPS binding studies
(Figure 11 and Figure 12). All experiments were performed in the presence of 100 mM
NaCl. Under these conditions, CRIP1a affects certain cannabinoid ligands, but not others.
The first obvious difference between Nol Eth, HU210, WIN, CP and the unaffected
cannabinoid ligands is efficacy. Nol Eth, HU210, WIN and CP all behave as high
efficacy agonists in these studies, with Emax values of 100% or greater in hCB1-HEK cells
without CRIP1a transfection (Figure 16). In the presence of CRIP1a the Emax value of Nol
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Eth to approximately 100%, whereas those of HU210, WIN and CP were reduced to ≤
80%. Incidentally, this value is approximately equivalent to the Emax values of the next
most efficacious ligands, MethA and Levo. One possibility is that CRIP1a reduces Gprotein activation by the CB1 receptor only when receptor activity is near maximal, thus
preferentially affecting high efficacy cannabinoid ligands.
Another, less likely, possibility is that CRIP1a affects cannabinoid ligands with
certain structural characteristics. WIN is a structurally distinct aminoalkylindol that
binds differentially to the CB1 receptor. A mutation at position 5.46 from Val to Phe in
the CB1 receptor alters the affinity of WIN for the CB1 receptor, while leaving the CB1
receptor affinity of HU210, CP, and AEA unaffected (Song et al. 1999). However, CP is
a nonclassical synthetic cannabinoid that is different from classical synthetic
cannabinoids but still resembles THC to a degree, making this hypothesis slightly less
probable than the efficacy hypothesis stated above. Furhermore, HU210 is a high
efficacy analog of the low efficacy partial agonist THC (Breivogel et al. 2001) and Nol
Eth is a high efficacy eicosanoid that is structurally related to the moderate efficacy
cannabinoid MethA (Sugiura et al. 1999). These structure-activity relationships argue
against structural features as the main determining factor in the effects of CRIP1a. Thus,
the effects of CRIP1a on acute CB1 receptor-mediated G-protein activation are more
likely to be dependent on the efficacy of the ligand.
CRIP1a may also affect ligands that stimulate certain Gi protein subtypes. WIN
activates all three Gi subtypes (see Introduction 1.3), whereas MethA only stimulates
Gi3 and acts as an inverse agonist for Gi1 and Gi2 (Mukhopadhyay and Howlett
2005). It is not known what Gi subtypes are specifically activated by the other
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cannabinoid ligands used in the [35S]GTPS binding experiments. CRIP1a may only
affect ligands that interact with Gi1, Gi2, or Go such as WIN, while leaving ligands
that primarily activate Gi3, such as MethA, unaffected.
CRIP1a attenuated the apparent ability of SR1 to act as an inverse agonist in the
[35S]GTPS binding studies. This finding suggests that CRIP1a inhibits the constitutive
activity of the CB1 receptor, in agreement with studies by Neihaus et al. (2007), which
found that CRIP1a inhibited constitutive inhibition of voltage gated Ca+2 channels (See
Introduction 1.6). Another possibility is that CRIP1a affects SR1 due to the Gi subtypes
it affects. SR1 acts as an inverse agonists for all three Gi subtypes (Mukhopadhyay and
Howlett 2005). One of these three subtypes may be preferentially affected by CRIP1a.
The juxtamembrane CB1 receptor C-terminus recognizes Gαi3 and Gαo, making them
more likely candidates for interference by CRIP1a than Gαi1 and Gαi2, which interact
with the C3 loop (Mukhopadhyay and Howlett 2001; Mukhopadhyay et al. 2002).
Furthermore, Gαi3 is associated with constitutive activity of the CB1 receptor, further
suggesting it may be a candidate for CRIP1a interference (Anavi-Goffer et al. 2007).
However, this hypotheses is mutually exclusive to the hypothesis that MethA is
unaffected by CRIP1a because it only activates Gi3. Future experiments examining the
effects of CRIP1a on CB1 receptor-Gα intereactions will need to be done to test these
hypotheses.
4.4 CRIP1a Attenuates Constitutive CB1 Receptor Activity & Spontaneous CB1
Receptor Mediated G-protein Activation in HEK Cells.
CRIP1a decreased the ability of SR1 to act as an inverse agonist in [35S]GTPS
binding studies, which suggests that CRIP1a decreases the constitutive activity of the
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receptor. Importantly, this is in agreement with the earlier Neihaus et. al. study, which
demonstrated a decrease in the inverse agonism of SR1 in electrophysiology studies using
a voltage-step Ca+2 current protocol. To further examine the effects of CRIP1a on
spontaneous CB1 receptor G-protein activation, [35S]GTPS binding experiments were
conducted over a range of Na+ concentrations (0-150 mM NaCl) (Figure 13). In addition,
several levels of ligand-induced CB1 receptor activation were examined [basal activity,
occupancy by the high effcicay agonist WIN (10 M), occupancy by the partial agonist
THC (6 M) and occupancy by the full inverse agonist SR1 (0.5 M SR1)]. Na+ acts as
a negative allosteric modulator of GPCR activity (Koski et al. 1982). As NaCl
concentrations decreased, CB1 receptor-mediated G-protein activation spontaneously
increased for both cell types for all conditions tested, as indicated by increased net
inhibition by SR1. CRIP1a decreased WIN simulated CB1 receptor activation at all NaCl
concentrations, in agreement with previous results obtained in the present studies using
100 mM NaCl (Fig 15 & 16)
The effects of CRIP1a became more evident as spontaneous CB1 receptor activity
increased, in agreement with the proposed hypothesis that CRIP1a inhibits spontaneous
CB1 receptor-mediated activity. CRIP1a significantly decreased G-protein activation for
all conditions tested at low NaCl concentrations (0, 10 & 25 mM NaCl). This finding
suggests that CRIP1a is able to affect the CB1 receptor, not only for when it is stimulated
by certain ligands, but under any conditions when the CB1 receptor is highly active. This
includes THC and basal conditions, which were not affected by CRIP at 100 mM NaCl
(Figure 11 & Figure 12).
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When basal [35S]GTPS binding was subtracted from the data at all NaCl
concentrations, the significant effects of CRIP1a at lower NaCl concentrations were lost
for all conditions (Figure 14). This finding suggests that CRIP1a decreased an equal
amount of spontaneous G-protein activity under all conditions tested, including basal.
This spontaneous G-protein activity seen at low Na+ concentrations was in addition to the
CB1 receptor-mediated G-protein activation that was modulated by the cannabinoid
ligands, as represented by the difference between the levels of [35S]GTPS binding in the
presence of a full agonist and an inverse agonist. However, the decrease in net WINstimulated CB1 receptor-mediated G-protein activation in the presence of CRIP1a was
statistically significant at higher NaCl concentrations (75, 100, 125 & 150 mM NaCl).
This finding suggests that CRIP1a can decrease G-protein activity in more than one
fashion. Not only does CRIP1a decrease spontaneous G-protein activation as seen at low
NaCl concentrations, but CRIP1a also net decreases WIN-stimulated CB1 receptormediated G-protein activation at moderate to high NaCl concentrations as seen in Figure
14.
Furthermore, these net stimulated [35S]GTPγS binding data were subject to AUC
analysis (Figure 15). CRIP1a significantly decreased the AUC for WIN-stimulated CB1
receptor-mediated G-protein activation in hCB-HEK cells compared to hCB-HEKCRIP1a cells. The AUC was not significantly different for THC or SR1 treatment
between the two cell types. However, there was a trend for CRIP1a to decrease the
apparent inverse agonism by SR1. The lack of SR1 effect may be due to the small
apparent constitutive CB1 receptor-mediated G-protein activity seen in hCB-HEK cells
(SR1 Emax value of –13.34  1.65% in hCB-HEK cells in the presence of 100 mM NaCl,
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Figure 16). Also, since Na+ and inverse agonists both stabilize the R state of the receptor,
the efficacy of inverse agonists is reduced in the presence of Na+ (Seifert and Wenzel
Seifert, 2002), which may also account for the lack of statistically significant effects of
CRIP1a on SR1.
To further examine the effect of CRIP1a on spontaneous CB1 receptor activity, the
same conditions were tested (basal, WIN, THC and SR1), at normal (100 mM) and low
(0 mM) NaCl concentrations, with the additional test condition of PTX pretreatment (Fig
16). PTX treatment ADP-ribosylates inhibitory Gi/o protein  subunits (Locht and
Antoine 1995), inhibiting their interaction with GPCRs, thus allowing a distinction
between GPCR-dependent G-protein activation and spontaneously active G-proteins.
Under normal, 100 mM NaCl, conditions, CRIP1a significantly decreased WINstimulated G-protein activity, in as seen in previous experiments. There were no
statistical differences for basal G-protein activity and SR1 inhibited G-protein activity
under 100 mM NaCl conditions between hCB1-HEK cells with and without CRIP1a coexpression. The lack of difference under basal conditions is in agreement with earlier
experiments. However, earlier experiments showed a decrease in inverse agonism by
SR1 in the presence of CRIP1a. This may be due to the very small amount of constitutive
activity seen in hCB1-HEK cells, which is generally 13% at 100 mM NaCl. Previous
experiments utilized an SR1 concentration-effect curve (Figure 11 & 12), which added
statistical power to the SR1 analysis that the current experiment lacked. PTX
pretreatment significantly decreased G-protein activation for all conditions in hCB1-HEK
cells. Interestingly, PTX pretreatment only significantly decreased WIN-stimulated Gprotein activity in hCB1-HEK-CRIP1a cells, while PTX pretreatment did not make a
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significant difference for basal or SR1-inhibited conditions. This finding suggests that
the presence of CRIP1a in hCB1-HEK-CRIP1a cells reduces G-protein activity to levels
indistinguishable from PTX pretreatment, further supporting the theory that CRIP1a
reduces spontaneous GPCR-dependent G-protein activation.
Once again, the absence of NaCl magnified the effect of CRIP1a. Under 0 mM
NaCl concentration, CRIP1a significantly decreased G-protein activation for the basal,
WIN and SR1 conditions, in agreement with the previous experiment (Figure 13). The
increase of spontaneous GPCR activity due to the absence of NaCl created a significant
difference for all conditions with and without PTX in hCB1-HEK-CRIP1a cells, indicating
that CRIP1a is not as effective as PTX in ameliorating spontaneous G-protein activation
under these conditions. Importantly, the presence of CRIP1a had no effect in cells that
were pretreated with PTX, such that G-protein activity in hCB1-HEK was not different
from that in hCB1-HEK-CRIP1a cells after PTX pretreatment PTX regardless of the
presence or absence of agonist or inverse agonist, indicating that all inhibitory effects of
CRIP1a are on GPCR-dependent G-protein activity, in agreement with the proposed
hypothesis.
In these experiments, the ability of CRIP 1a to reverse the apparent inverse
agonism of SR1 was not detected as in earlier experiments (Figure 12). As stated earlier,
this may be due to the relatively low amount of constitutive CB1 receptor activity in hCBHEK cells. Furthermore, the concentration of SR1 used, which was maximally effective,
may have been high enough to affect GPCRs other than the CB1 receptor under certain
conditions. At concentrations over 1 M, SR1 is able to affect both basal and WIN or
AEA-induced stimulation of [35S]GTPS binding in CB1 receptor knockout mouse brain
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membranes (Breivogel et al. 2001). This finding raises the possibility that SR1 affects
GPCRs other than the CB1 receptor near this concentration. Additionally, in a study
characterizing SR1-inhibited G-protein activity by measuring [35S]GTPS binding in rat
cerebellar membranes found that SR1 acts as a competitive antagonist at nM
concentrations, whereas it inhibits basal receptor-mediated G-protein activity at
micromolar concentrations (Sim-Selley et al. 2001). This finding also suggests that SR1
may affect GPCRs other than the CB1 receptor, and/or that SR1 binds to different sites on
the CB1 receptor to produce inverse agonist versus competitive agonist effects. It is
conceivable that at the concentration used in these studies, SR1 may be partially affecting
receptor activity other than that of the CB1 receptor, confounding interpretation of the
effect of CRIP1a on CB1 receptor-mediated G-protein activation. Some evidence for this
possibility is seen in the present study. [35S]GTPS binding studies utilizing a
concentration effect curve for SR1 show a reduced ability for CRIP1a to inhibit the
apparent inverse agonist effects of SR1 at the highest concentrations examined (Figure
11). This effect may be due to interference by other non-CB1 receptor-mediated effects
of SR1. Therefore, the ability of CRIP1a to inhibit the constitutive activity of the CB1
receptor may not be as apparent at high SR1 concentrations.
Another potentially confounding variable in experiments examining effects of
CRIP1a on constitutive CB1 receptor activity is the possibility of the presence of
endogenous cannabinoids. The effects of CRIP1a on apparently spontaneous CB1
receptor-mediated G-protein activity could be misinterpreted if in fact endogenous
cannabinoids are contributing to this basal activity. To ensure that differences in basal Gprotein activation seen between hCB1-HEK and hCB1-HEK-CRIP1a cells were due to the
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presence of CRIP1a and not differences in endogenous cannabinoid expression,
endocannabinoid levels were measured in whole cells and membrane preparations from
each cell line (Table 4). No detectable levels of AEA or 2-AG were found in either
preparation of either cell line.
Collectively, the data indicate that CRIP1a decreases not only constitutive activity,
and high efficacy agonist-stimulated stimulated CB1 receptor-mediated G-protein
activity, but possibly non CB1 receptor-mediated G-protein activity under any conditions
when spontaneous GPCR activation is high.
4.5 CRIP1a Decreases CB1 Receptor Downregulation, but not CB1 Receptor
Desensitization.
To assess the effect of CRIP1a on CB1 receptor regulation by prolonged agonist
treatment, hCB1-HEK cells (± CRIP1a co-expression) were pretreated for four hours with
agonist (10 µM WIN, 6 µM THC or vehicle), followed by MethA-stimulated [35S]GTPS
binding (Figure 17). MethA was chosen as the stimulating ligand in these studies
because CRIP1a did not affect its ability to acutely stimulate CB1 receptor-mediated Gprotein activation in earlier studies (Figure 11 and Figure 12). Both the high efficacy
agonist WIN, and to a lesser extent, the partial agonist THC, caused significant
desensitization of the CB1 receptor, as indicated by decreased Emax values for MethA
stimulated G-protein activation in agonist pretreated cells. However, the presence of
CRIP1a did not significantly affect this desensitization, in opposition to the proposed
hypothesis that CRIP1a could sterically interfere with GPCR C-terminal interacting
proteins that mediate homologous desensitization, such as GRKs or -arrestins.
Nonetheless, the inability of CRIP1a to affect CB1 receptor desensitization is not
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surprising. CRIP1a binds to the last nine amino acids of the CB1 receptor C-terminal tail,
which is some distance from the CB1 C-terminal region required for GRK or -arrestin
binding and CB1 receptor desensitizaiton (aa 419-438) (Jin et al. 1999), therefore making
steric hinderance of GRK or -arrestin binding less likely.
Interestingly, the MethA EC50 values for WIN and THC pre-treated cells were
significantly increased in both hCB1-HEK ( CRIP1a) cell lines (Table 5), as a result of
rightward shifts of the MethA concentration-effect curves (Figure 17). For many GPCRs,
only a fraction of available receptors need to be occupied for an agonist to produce a full
functional response. Further receptor occupancy beyond the maximal response produces
no further stimulation, and this situation is referred to as receptor reserve. Receptor
reserve can be measured in a biological system by inactivating an increasing percentage
of receptors, such as with an irreversible antagonist, which will produce a progressive
rightward shift in the dose-response curve that is subsequently followed by a depression
in the maximal response. CB1 receptors in particular are known for their large receptor
reserve for downstream cannabinoid actions in the central nervous system (Gifford et al.
1999). However, the receptor reserve for CB1 receptor mediated G-protein activation
may not be as large, as demonstrated in heterozygous CB1 knockout mice (Selley et al.
2001), but there could be receptor reserve for G-protein activation in transfected cell
lines, as shown with the μ opioid system comparing CHO cells transfected with μ opioid
receptor to rat brain (Selley et al. 1998). In this study, the decrease in MethA EC50 values
is indicative of loss of receptor reserve due to downregulation of the CB1 receptor, as
seen in the next set of experiments measuring loss of receptors in response to WIN and
THC pretreatment.
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The effects of CRIP1a on CB1 receptor downregulation was determined using the
same four hour drug pretreatment followed by [3H]SR141716A saturation analysis to
determine changes in CB1 receptor number (Figure 18). In hCB1-HEK cells, the partial
agonist THC caused a robust CB1 receptor downregulation, while the full agonist WIN
caused less downregulation. CRIP1a attenuated the less substantial CB1 downregulation
induced by WIN, but did not significantly attenuate the robust downregulation induced
by THC, although there appeared to be a trend toward a decrease. [3H]SR141716A KD
values were unaffected by drug treatment (Table 6), indicating the effective removal of
WIN and THC that were used for the pretreatment prior to assay. This finding suggests
that rightward shifts in the MethA concentration-effect curves induced by drug
pretreatment were due to a loss in receptor reserve and not residual pretreatment drug in
the membranes. One possible explanation for the differential ability of CRIP1a to inhibit
WIN- versus THC-induced CB1 receptor downregulation may be that CRIP1a weakly
sterically hinders the interaction of -arrestin with the phosphorylated receptor. arrestins are sizable (~48 kDa) proteins that interact near the C-terminal tail of the CB1
receptor and interact with GPCRs strongly enough to relocate them from signaling
complexes to clathrin-coated pits (Reiter and Lefkowitz 2006). It is possible that in this
cell model CRIP1a is able to sterically interference with WIN-stimulated interactions of
-arrestin and the CB1 receptor in a way that THC is able to overcome.
Another possibility is differential induction of the -arrestin types by THC and
WIN. HEK 293 cells contain both -arrestin 1 and 2. In HEK 293 cells transfected with
the µ opiod receptor (µOR), the µOR interacts with -arrestin 2 only when the partial
agonist morphine is used. However, when the full agonist etorphine is utilized, the µOR
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receptor interacts with both -arrestin 2 and 1 (Bohn et al. 2004). Furthermore, the
genetic knockout of -arrestin 2 in mice selectively enhanced the behavioral effects of
THC, while leaving the effects of CP, MethA, JWH-073 and O-1812 unaffected
(Breivogel et al. 2008). Therefore, THC may be preferentially affect -arrestin 2 binding
to the CB1 receptor. It is possible that with the CB1 receptor, THC and WIN cause
differential recruitment of -arrestin 2 and 1, and that CRIP1a preferentially interferes
with the binding of one of these isoforms, namely -arrestin 1.
Alternatively, CRIP1a may attenuate WIN-induced CB1 receptor downregulation
by interfering with GASP1 binding to the CB1 receptor. GASP1 is required for ligandinduced downregulation of the CB1 receptor (Martini et al. 2007), but is not directly
involved in CB1 receptor desensitization, thus potentially explaining the ability of
CRIP1a to interfere with downregulation but not desensitization, as hypothesized. The
robust downregulation induced by THC compared to WIN may indicate that THC
induces greater CB1 receptor/GASP1 interactions than WIN. CRIP1a may not sterically
hinder this stronger interaction induced by THC as effectively as the putatively weaker
interaction of CB1 receptor to GASP1 induced by WIN. This difference may account for
CRIP1a preferentially affecting WIN over THC-mediated downregulation.
Downregulation by WIN could also be more greatly affected by CRIP1a because
CRIP1a inhibits acute G-protein activation by WIN, which could result in impairment of
Gβγ recruitment of GRK 2/3. Another related possibility is that CRIP1a affects WINstimulated CB1 receptor regulation due to the specific G subtypes that WIN activates, as
hypothesized for acute CB1 receptor-mediated G-protein activation (see Conclusions 4.3).
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However, these explanations seem less likely as CRIP1a affected downregulation of the
CB1 receptor without affecting CB1 receptor desensitization.
The time course used in the CB1 receptor desensitization and downregulation
experiments may have played a part in the observed results. CRIP1a had no effect on
desensitization of the CB1 receptor after four hours of drug exposure (Figure 17).
Maximal endocytosis of the CB1 receptor is observed in desacetyllevonantradol (DALN)
exposed CB1-HEK cells after 1 hour (Keren and Sarne 2003). CRIP1a may affect
desensitization on a shorter time scale, before maximal desensitization is reached. Thus,
if CRIP1a inhibits the rate of desensitization but not the maximal level of desensitization,
then it is possible that maximal desensitization was achieved well before 4 hours, and the
effect of CRIP1a was not evident at this time point. Future experiments should examine
the effects of CRIP1a on desensitization in time increments less than 1 hour.
Additionally, effects of CRIP1a on THC-induced downregulation may have been apparent
on a shorter time scale. CB1 receptors are downregulated by more than 75% in WINexposed CB1-HEK cells after 3 hours (Martini et al. 2007). Subsequent experiments
examining the effects of CRIP1a on downregulation may yield significant results at one
and two hour time points, regardless of the agonist occupying the receptor.
Lastly, the cannabinoid ligand concentrations used may have played a role in the
observed effects of CRIP1a on CB1 receptor desensitization and downregulation.
Maximally effective concentrations of WIN (10 µM) and THC (6 µM) were used in both
experiments. Desensitization is increased by increasing WIN concentrations as measured
by cannabinoid inhibition of Ca+2 spiking activity in hippocampal neurons (Kouznetsova
et al. 2002). Also, increasing concentrations of DALN increased CB1 receptor
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endocytosis in CB1-HEK cells (Keren and Sarne 2003). Therefore, lower cannabinoid
concentrations may be used to reveal subtle effects of CRIP1a on the potency of agonists
to induce CB1 receptor desensitization and downregulation. Future experiments
examining the effects of CRIP1a on CB1 receptor regulation should include concentrationeffect curves that begin at sub-EC50 ligand concentrations.
4.6 CRIP1a and Downstream Signaling of CB1 Receptors
The effects of CRIP1a on downstream CB1 receptor mediated inhibition of
forskolin stimulated cAMP generation were measured via liquid phase cAMP radioassay
(Figure 19). CRIP1a did not alter cAMP levels in cells treated with WIN, THC or vehicle.
However, interestingly, CRIP1a reversed the apparent inverse agonism of SR1. The
ability of CRIP1a to decrease inverse agonism, a measure of the constitutive activity of
the CB1 receptor, in cAMP experiments agrees with the results obtained when measuring
the effects of CRIP1a on constitutive CB1 receptor activity in [35S]GTPS binding
experiments. Moreover, these results are in agreement with the ability of CRIP1a to
decrease CB1 receptor-mediated tonic inhibition of voltage-gated Ca+2 channels by
Neihaus et al. (2007). Therefore, CRIP1a appears to decrease the spontaneous modulation
of certain downstream effectors by CB1 receptors, as hypothesized.
The effects of CRIP1a on downstream CB1 receptor-stimulated ERK 1/2
phosphorylation were examined via immunoblot analysis using an antibody that is
specific for phosphorylated ERK 1/2 (Figure 20). WIN, and to a lesser extent THC,
increased ERK 1 and 2 phorsphorylation, and SR1 inhibited ERK 1 and 2
phosphorylation (Figure 21). There was no statistical differences in agonist-stimulated
ERK 1 or 2 phosphorylation between hCB1-HEK cells with and without CRIP1a co-
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expression, suggesting that CRIP1a had no significant effect on downstream ERK 1/2
signaling by CB1 receptors.
However, it should be noted that there was a trend for CRIP1a to reverse the
ability of SR1 to produce inverse agonism in the phosphorylation of ERK 1 and 2.
However, this effect was also not statistically significant. It is possible that this
immunblot assay protocol was not sensitive enough to detect differences between hCB1HEK cells with and without CRIP1a co-expression. Future protocols more sensitive to
changes in CB1 receptor-dependent phorsphorylation of ERK 1 and 2 may yet detect an
effect by CRIP1a. Furthermore, future experiments could utilize a concentration-effect
curve, as CRIP1a may lead to potency changes in the ability of cannabinoids to
phosphorylate ERK 1/2. A similar argument could be made for agonist-inhibited cAMP
generation above.
Furthermore, the concentration of SR1 used, which was maximally effective, may
have been too high to see significant effects of CRIP1a on the CB1 receptor-mediated
phosphorylation of ERI 1/2. At this dose it might have GPCR effects not specific to the
CB1 receptor that may be affecting the results, as discussed for PTX pre-treatment
experiments in Conclusions 4.4.
Considering the effect of CRIP1a on downstream signaling to both cAMP and
ERK 1/2, it seems probable that CRIP1a affects some downstream signals but not others.
In addition, CRIP1a could differentially modulate G versus G-mediated signaling.
However, CRIP1a decreased the constitutive CB1-mediated inhibition of cAMP, which is
modulated mainly by G1 (Howlett et al. 2002), and decreased the constitutive inhibition
of voltage-gated Ca+2 channels (Niehaus et al. 2007), which is modulated by G
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(Herlitze et al. 1996). Thus CRIP1a is apparently able to modulate G-protein mediated
downstream signals despite whether Gα or Gβγ is required for downstream signaling.
Therefore, it remains uncertain why SR1-stimulated cAMP generation was significantly
inhibited by CRIP1a co-expression, whereas SR1-inhibited ERK 1/2 phosphorylation was
not. Aside from methodological issues, it is possible that there is greater amplification of
the cAMP signal provided by the catalytic action of the adenylyl cyclase enzyme, relative
to less amplification in the signaling cascade leading to ERK 1/2 phosphorylation. If so,
then this differential amplification might explain the greater signal for SR1-modulated
activity in the cAMP than in the ERK 1/2 experiments.
4.7 Mouse hippocampal CRIP1a expression in response to THC administration.
Expressions of various regulators of CB1 receptor signaling are altered in
response to chronic cannabinoid treatment. Chronic, but not acute, THC treatment
upregulates GRK2, GRK4, -arrestin 1, and -arrestin 2 (Rubino et al. 2006). To
determine if chronic drug administration could alter CRIP1a levels in the hippocampus,
mice were administered ramping doses of THC and their hippocampi were dissected and
immunoblotted for CRIP1a expression (Figure 22). CRIP1a levels were not different
between mice administered THC or vehicle. Chronic THC administration did not alter
CRIP1a expression in the hippocampus of mice in response to repeated ramping doses of
THC administration. This was not in agreement with the predicted hypothesis that THC
treatment would affect CRIP1a levels. GRKs and β-arrestins are proteins involved in CB1
receptor adaptation to prolonged agonist treatment, and therefore it is not surprising that
prolonged agonist treatment affects their expression. CRIP1a regulates the acute and
constitutive responsiveness of the CB1 receptor; therefore regulation of CRIP1a
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expression in response to prolonged agonist occupancy might be unnecessary. However,
it would be interesting to examine the effects of WIN on CRIP1a expression, as the
downregulation induced by the CB1 receptor occupancy by WIN was affected by the coexpression of CRIP1a.
4.8 Stoichiometric Relationship of CRIP1a/CB1 Receptor in mCB1-CHO Cells with
and without CRIP1a Co-expression.
CB1 receptor (Table 7) and CRIP1a levels (Figure 22) were quantified in mCB1CHO cells with and without stable co-transfection of CRIP1a, and the CRIP1a/CB1
receptor molar stoichiometric relationship was calculated from these values (Table 8).
mCB1-CHO cells without CRIP1a transfection contained a substantial amount of CRIP1a.
The stoichiometric molar ratio in mCB1-CHO cells without CRIP1a transfection was
greater than hCB1-HEK cells with stable CRIP1a transfection (Table 3). Stable CRIP1a
transfection further increased CRIP1a expression dramatically in mCB1-CHO cells, as
hypothesized, creating a nearly 2,000-fold molar excess of CRIP1a/CB1 receptor, which
can be viewed as CRIP1a over-expression.
4.9 CRIP1a Modulation of Acute CB1 Receptor Mediated G-protein Activation in
CHO Cells.
The effects of CRIP1a on acute CB1 receptor-mediated G-protein activation were
examined in [35S]GTPS binding studies using WIN, THC and SR1 in mCB1-CHO cell
membranes with and without CRIP1a over-expression (Figure 24 and Figure 25).
Notably, further over-expression of CRIP1a in mCB1-CHO-CRIP1a cells further decreased
constitutive activity of CB1 receptors compared to mCB1-CHO cells which already
contained ample levels of CRIP1a, as hypothesized. This finding raises the further
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possibility that CRIP1a did not reliably reduce constitutive CB1 receptor activity in all
experiments in hCB1-HEK-CRIP1a cells (especially under low sodium concentrations)
because it was not expressed at a sufficiently high molar ratio compared to CB1 receptor
levels.
Surprisingly, CRIP1a over-expression in mCB1-CHO cells increased maximal CB1
receptor-mediated G-protein activation by both WIN and THC, in opposition to the
proposed hypothesis. Therefore, stoichiometric relationship could be a critical
determinant in how CB1 receptor-mediated G-protein activation responds acutely to the
presence of CRIP1a. Over-expression of CRIP1a in co-transfected CB1-CHO cells caused
augmentation of acute agonist-stimulated CB1 receptor-mediated G-protein activation,
rather than the attenuation seen at near physiological CRIP1a levels present in CRIP1a cotransfected CB1-HEK cells.
Alternatively, the effects of CRIP1a may be cell type dependent. CHO and HEK
cell lines are two of the most commonly used cell lines in biomedical research. CHO
cells, derived from Chinese Hamster Ovary cells (Puck et al. 1958) are the most utilized
cell line in the pharmaceutical large scale production of therapeutic protein products,
accounting for billions of dollars in products annually (Andersen and Krummen 2002).
However, the genome of CHO cells is not well characterized (Wlaschin et al. 2005). In
contrast, HEK cells, derived from Human Embryonic Kidney cells (Graham et al. 1977)
are postulated to be derived from a neuronal cell lineage (Shaw et al. 2002). Notably, a
HEK genomic database at the University of Florida
(http://www.mbi.ufl.edu/~shaw/293.html) reveals that HEK cells contain a surprising
amount of neuron-specific proteins including several neurofilament subunits and alpha
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internexin, as well as GPCRs, such as dopamine (D2) receptors and neurotensin (NTR2)
receptors. Additionally, CHO and HEK cells are different in the subtypes of Gi that
they express. CHO cells express Gi2 and Gi3, but not Gi1 (Gettys et al. 1994). On
the other hand, HEK cells express Gi1 and Gi3 but not Gi2 (Law et al. 1993).
Therefore, CRIP1a‟s differential effects on acute agonist stimulated G-protein activity
may be due to the differences in the proteome of HEK and CHO cell types, rather than to
differences in the stoichiometric relationships between CRIP1a and CB1 receptor in the
two cell lines.
Future experiments examining the effects of genetic silencing of CRIP1a
expression using shRNA in CHO cells may be able to answer the question of cell type
specificity. In this case CRIP1a silencing could be expected to reverse both the
attenuation of constitutive activity and augmentation of agonist stimulated CB1 receptormediated G-protein activation in mCB1-CHO cells. It is also possible that partial
silencing of CRIP1a expression in mCB1-CHO cells, to a molar ratio similar to that
obtained in hCB1-HEK-CRIP1a cells, could produce attenuation of full agonist-stimulated
G-protein activation.
Another explanation may be that the CRIP1a differentially affects the human and
mouse CB1 receptor. However, this explanation is less likely due to expression of CRIP1a
throughout the vertebrates and the identical amino acid composition of the last 9 amino
acids of both murine and human CB1 receptors, which compromise the CRIP1a binding
site.
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4.10 CRIP1a Does Not Affect Spontaneous CB1 Receptor Mediated G-protein
Activation in CHO Cells.
Varying NaCl concentrations were used to determine the effect of CRIP1a on
spontaneous G-protein activation in mCB1-CHO cells with and without CRIP1a overexpression in the presence of WIN, THC, SR1 and basal conditions (Figure 26). No
effect of CRIP1a on spontaneous or agonist-stimulated G-protein activation was found,
thus rejecting the proposed hypothesis. This was in contrast to results seen in earlier
ligand concentration-effect curves in the presence of 100 mM NaCl, in which CRIP1a
over-expression suppressed the inverse agonist effects of SR1 and augmented CB1
receptor-mediated G-protein activation by agonists.
The most likely explanation for these different results involves the manner in
which the membrane preparations for these experiments were prepared. Unlike all other
experiments in this dissertation, mCB1-CHO cells (±CRIP1a) were grown in flasks, drugtreated, homogenized and frozen back into aliquots which were later used in [35S]GTPS
binding studies. Freeze-thawing membrane preparations may impair the acute signaling
of the CB1 receptor or its modulation by CRIP1a and explain the variability and lack of
effect of CRIP1a seen in these results. Also notable, fresh membrane preparations were
used in initial [3H]SR141716A saturation analysis of hCB1-HEK and mCB1-CHO cell
lines with and without CRIP1a transfections (Table 3 and Table 8) . However, excess
remaining protein from [35S]GTPS binding studies was often frozen back and used in
[3H]SR141716A saturation analysis to confirm unchanging CB1 receptor numbers. No
differences between fresh and frozen membrane preparations were seen in the results of
[3H]SR141716A saturation analysis. This finding is unsurprising as freezing back
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membrane preparations is more likely to upset the more delicate signaling process
assayed in receptor-stimulated [35S]GTPS binding studies rather than the number of CB1
receptors determined by high affinity [3H]SR141716A saturation analysis.
Another potential explanation is the comparison of stoichiometric relationship
between the HEK and CHO cell line models. mCB1-CHO cells, unlike hCB1-HEK cells
contain a substantial amount of CRIP1a, resulting in a molar excess of CRIP1a over CB1
receptor that is merely enhanced by CRIP1a over-expression in this cell line. Therefore,
comparing an excess of CRIP1a to an even greater excess of CRIP1a relative to the CB1
receptor might result in no discernable effects of CRIP1a over a range of Na+
concentration. However, this explanation is less likely, as an effect of CRIP1a on
constitutive and agonist-induced CB1 receptor-mediated G-protein activity was seen at
100 mM NaCl.
4.11 CRIP1a Transfection Affects 2-AG Expression in mCB1-CHO (±CRIP1a) Cell
Lines.
Levels of two endocannabiniods, AEA and 2-AG were determined via LC-ESIMS-MS for mCB1-CHO cells with and without CRIP1a over-expression (Table 9). No
detectable levels of AEA were found in either cell line in either whole cell or membrane
preparations. Contrariwise, whole cell preparations of mCB1-CHO cells contained small
amounts of 2-AG which were significantly increased in CRIP1a over-expressing mCB1CHO-CRIP1a cells, which was not predicted by the hypothesis. 2-AG can act as an
autocrine mediator, as it is responsible for the postsynaptic slow self-inhibition of
neocortical low-threshold spiking interneurons (Marinelli et al. 2008). CRIP1a coexpression may feedback onto 2-AG synthesis, thus increasing 2-AG levels in mCB1-
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CHO- CRIP1a cells. However, this difference cannot explain the results seen in earlier
[35S]GTPS binding studies comparing the two CHO cell lines, as no detectable levels of
2-AG were found in the membrane preparations of either cell line. Nonetheless,
downstream signaling experiments utilizing mCB1-CHO cells with and without CRIP1a
over-expression may not accurately reflect the effects of CRIP1a on basal CB1 receptor
activity due to the increase in 2-AG in CRIP1a over-expressing whole cells. Downstream
experiments utilized whole cells which were drug treated and harvested for analysis of
cAMP and pERK 1/2 levels, which could be affected by the endogenous presence of 2AG. Conversely, endogenous cannabinoids could not have affected downstream cAMP
and phosphorylated ERK 1/2 signals in hCB1-HEK cells with and without CRIP1a
transfection, as no endogenous cannabinoids were detected in these cell lines.
4.12 Summary of CRIP1a Conclusions
In summary, CRIP1a inhibits the constitutive activity of the CB1 receptor (Figure
27, Table 10). Additionally, CRIP1a modulates acute CB1 receptor mediated G-protein
activation of high efficacy ligands in a manner that is cell type dependent and/or
dependent on the stoichiometric relationship of CRIP1a to the CB1 receptor. CRIP1a does
not affect the maximal level of CB1 receptor desensitization, but does modify CB1
receptor downregulation induced by WIN. Lastly, CRIP1a affects downstream
constitutive CB1 receptor-mediated signaling for cAMP inhibition, but not the
phosphorylation of ERK 1/2. CRIP1a also appears to modulate 2-AG production only in
certain cell types (i.e. CHO) when expressed as sufficiently high levels.
Overall, CRIP1a mediates numerous CB1 receptor effects while being a small 17
kD protein. This observation, in tandem with the fact that CRIP1a contains a PDZ Class I
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ligand, suggests that CRIP1a mediates it effects in concert with other proteins to which it
binds. For example, CRIP1a may bind to members of the cell cytoskeleton, thus
stabilizing the CB1 receptor and preventing its constitutive activation and activation by
high efficacy ligands. A possible parallel example to this may be the recently discovered
Homer proteins, which bind to metabotropic glutamate (mGlu) receptors and cytoskeletal
Shank proteins. Homer proteins decrease the constitutive activity of the mGlu receptors,
much like CRIP1a decreases the constitutive activity of the CB1 receptor (Ango et al.
2001; Bockaert et al. 2004). Future studies should seek to discover other CRIP1a protein
binding partners.
Physiologically, the ability of CRIP1a to affect high efficacy ligands while leaving
moderate and low efficacy ligands unaffected may be important in the differential
regulation of endocannabinoid signals generated by the CB1 receptor. For instance, AEA
is a partial agonist (Breivogel et al. 1998), as is its stable analog, MethA, used in the
present study. CRIP1a did not affect MethA stimulation of the CB1 receptor, and
presumably will not affect stimulation by its partial efficacy analog AEA. However, 2AG is a full agonist (Stella et al. 1997), and noladin ether, another high efficacy agonist
that is structurally similar to 2-AG, was affected by CRIP1a in this study. Therefore, it is
reasonable to speculate that CRIP1a will modify the CB1 receptor-mediated G-protein
signal generated by 2-AG but not by AEA. Therefore, under physiological conditions,
CRIP1a may affect the signaling of certain endogenous cannabinoids but not others.
Overall, CRIP1a may be key to modulating CB1 receptor functions; allowing the
generation of certain therapeutic responses while minimizing deleterious side effects. For
example, pharmacological modulation of CRIP1a, rather than direct modulation of the

127
CB1 receptor, may allow the therapeutic modulation of high efficacy endocannbinoid
effects while avoiding any side effects generated by the modulation of partial efficacy
endocannabinoids.
In conclusion, CRIP1a is an important member of the CB1 receptor receptosome
that regulates both constitutive activity of the CB1 receptor and ligand-mediated CB1
receptor activity in a manner that differentially affects high efficacy and partial agonists,
both of exogenous and endogenous origin. Additional evidence suggests that CRIP1a can
also attenuate agonist-induced CB1 receptor downregulation and constitutive CB1
receptor modulation of a subset of effector pathways. These properties suggest that
CRIP1a may someday be targeted pharmacologically to allow more effective
manipulation of CB1 receptor activities to therapeutic advantage.
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Figure 27. The effects of Cannabinoid Receptor Interacting protein (CRIP1a) on CB1
receptor function. CRIP1a inhibited constitutive G-protein activation by the CB1 receptor.
CRIP1a decreased WIN and CP-stimulated acute G-protein activation by the CB1 receptor
in HEK cells and increased WIN and THC-stimulated acute G-protein activation by the
CB1 receptor in CHO cells. CRIP1a did not affect desensitization, but did attenuate
downregulation induced by WIN occupancy of the CB1 receptor. Downstream, CRIP1a
decreased the constitutive inhibition of adenylyl cylase by the CB1 receptor. The effects
of CRIP1a were dependent on the stoichiometric ratio of CRIP1a/CB1 receptors.
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CRIP1a Effects?
CB1 Receptor
Expression
G-protein Activation
Receptor
Desensitization
Receptor
Downregulation
Ca+2 Channel
Inhibition
Adenylyl Cyclase
Inhibition
ERK 1/2

Constitutive
No (1, 2)

Agonist-Mediated
None apparent.

Yes (2)
None apparent.

Yes (2)
No (2)

None apparent.

Yes (2)

Yes (1)

No (1)

Yes (2)

No (2)

No (2)

No (2)

Table 10. Concluding summary of the effects of CRIP1a on CB1 receptor mediated
activity. References: (1) Neihaus et al. (2007), (2) Results from the current dissertation.
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